Semaglutide
NN9535 · Ozempic · Wegovy · Rybelsus
FDA-APPROVED · GLP-1 RECEPTOR AGONIST
▓ 624 indexed citations across PubMed (262), ClinicalTrials.gov (297), EuropePMC (65).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Background
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardiovascular events. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold as a generic drug by several drug companies in the Indian and Canadian markets, and worldwide by its originator, Novo Nordisk, under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management, weight loss, and metabolic-associated steatohepatitis.
Mechanism of action
Researched effects
Reported efficacy (trial readout)
-
Weight Loss 15%
~15% (STEP 1, 68wk)
High confidencen=8,8032024 -
Visceral Fat Reduction 40%
Lancet Diabetes Endocrin (Phase 3, 68wk, n=199)
High confidencen=199Phase 32022
Trial-efficacy data current as of November 16, 2026.
Live evidence
FDA label safety
WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for…
4 CONTRAINDICATIONS OZEMPIC is contraindicated in patients with: • A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . • A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.8 )] . • Personal or family history of MTC or in patients with MEN 2. ( 4 ) • Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC. ( 4 )
Active clinical trials 313
- Semaglutide Effects on Sperm Concentration in Overweight Infertile Men
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
- A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
- GLP-1R Agonist Treatment for Opioid Use Disorder
- GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
Reported adverse events 8,259
Events spontaneously reported to the FDA FAERS database since 2015. A report does not establish that the drug caused the event, and counts do not reflect how often it occurs. Discuss any concern with a clinician.
FDA FAERS →Live signals refreshed daily. Current as of November 18, 2026.
Dosing reported in literature
0.25 mg SC weekly (Wegovy/Ozempic label starting dose, escalate monthly to label max 2.4 mg weekly per STEP-1 protocol) 123; oral 3 mg daily Rybelsus starting dose (target 14 mg daily)
→ FDA Wegovy/Ozempic/Rybelsus prescribing information (starting doses); STEP-1 escalation schedule (PMID 33567185)
Known concerns
Top-ranked picks
10 pre-curated authoritative sources, ranked by journal tier and study weight.
- Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
- Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
- Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
- GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.
- Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.
- Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease.
- Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
- Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.
Full citation library
Year distribution
No references match — clear filters.
Meta-Analyses
45-
1.
We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in…
-
2.
Some concerns persist regarding the safety of semaglutide. The objective of this updated meta-analysis is to assess the risk of acute pancreatitis with the use of semaglutide, assessing the results according to the different administration regimens. We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis. This meta-analysis was performed in line with PRISMA guidelines. A global and stratified analysis according to the…
-
3.
The PIONEER and SUSTAIN serial trials are designed to assess the efficacy outcomes with semaglutide in patients with type 2 diabetes, but are not powered to assess various safety outcomes. We sought to assess the risk of semaglutide in leading to various serious adverse events (SAEs) in patients with type 2 diabetes. Studies eligible for inclusion were the PIONEER and SUSTAIN trials of semaglutide. We conducted meta-analysis to generate pooled risk ratios (RRs) and 95% confidence intervals (CIs)…
-
4.
The aim of the study was to compare the effectiveness of tirzepatide versus semaglutide in producing weight loss. A systematic search was conducted in databases PubMed, Scopus, and Web of Science on January 22, 2025, using search terms ("tirzepatide," "semaglutide," and "weight loss") and their alternatives, which yielded 751 studies in total. After deduplication, title/abstract and full text screening was conducted, and studies were assessed based on the eligibility criteria. After extracting t…
-
5.
Spinal fusion is a widely performed surgical procedure for treating various spinal disorders, with lumbar fusion showing remarkably rapid growth worldwide. Despite positive outcomes after the procedure, it carries significant complications, most notably pseudarthrosis. Compromised blood supply is a key factor disrupting normal bone fusion, making optimal vascularization crucial for successful outcomes. Glucagon-like peptide-1 (GLP-1) receptor agonists, primarily used for diabetes management, dem…
-
6.
Heart failure with preserved ejection fraction (HFpEF) affects 32 million people worldwide and is responsible for tens of billions of dollars in healthcare expenditure annually, with costs primarily driven by hospitalizations. HFpEF is notoriously difficult to treat, but emerging studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be effective therapies. We performed a systematic review and meta-analysis of six randomized controlled trials with 5564 total participants…
-
7.
Semaglutide 2.4 mg is the reference pharmacotherapy for weight management, yet many patients do not reach ambitious weight-loss targets. CagriSema, a fixed-dose combination of cagrilintide and semaglutide, may offer additional benefit through complementary mechanisms. We quantified its incremental efficacy and safety against semaglutide 2.4 mg monotherapy in adults with overweight or obesity, with and without type 2 diabetes. This PRISMA 2020-compliant review (PROSPERO CRD420261380458) searched…
-
8.
While injectable GLP-1 receptor agonists like semaglutide have demonstrated clear cardiovascular benefits in type 2 diabetes mellitus (T2DM), the role of oral incretin-based therapies, including oral semaglutide and DPP-4 inhibitors-remains less well defined. Comprehensive evaluation of their cardiovascular efficacy is warranted. What are the cardiovascular outcomes associated with oral incretin-based therapies, specifically oral semaglutide and DPP-4 inhibitors, in patients with T2DM compared t…
-
9.
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular risk in patients with type 2 diabetes mellitus (T2D), evidence in heart failure (HF) has expanded across diverse trial populations and HF phenotypes but remains fragmented. We therefore performed an integrated systematic review and meta-analysis to evaluate the effects of GLP-1 RAs across the spectrum of HF using complementary trial-level and phenotype-based analyses. PubMed, Embase, and Web of Science were syst…
-
10.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for Type 2 diabetes (T2DM) and obesity, but emerging evidence links them to nonarteritic anterior ischemic optic neuropathy (NAION). Whether this risk differs across agents and the underlying mechanisms remains unclear. We aimed to compare the risks of NAION associated with different GLP-1RAs and to explore the potential molecular mechanisms underlying this adverse reaction. A network meta-analysis was performed to quantitative…
-
11.
Semaglutide is prescribed in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes (T2DM). However, its potential impact on tumorigenesis has prompted considerable debate. The meta-analysis was conducted in accordance with PRISMA 2020 guidelines. We searched Web of Science, PubMed, Embase, and ScienceDirect for eligible randomized controlled trials (RCTs). The outcome was the risk of overall, benign and malignant neoplasms. The pooled results were expresse…
-
12.
To compare the cardiorenal efficacy and safety of finerenone, sodium-glucose cotransporter 2 inhibitors (SGLT2i), semaglutide and finerenone-SGLT2i combination therapy in diabetic kidney disease (DKD). PubMed, Embase and CENTRAL were searched through July 9, 2026 for randomized trials involving adults with Type 2 diabetes and DKD. A frequentist network meta-analysis estimated risk ratios (RRs) with 95% confidence intervals (CIs) for cardiorenal and safety outcomes. Ten randomized datasets involv…
-
13.
Metabolic bariatric surgery is a highly effective weight-loss intervention. Nevertheless, a non-negligible proportion of patients experience a suboptimal clinical response, which may present as insufficient weight loss or weight regain after an initial loss. In these cases, weight management pharmacotherapy can be considered. We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in…
-
14.
Semaglutide and tirzepatide produce substantial weight loss during treatment, but the trajectory of weight regain after discontinuation remains uncertain. To estimate post-discontinuation weight-regain trajectories and explore predictors of faster regain. We used published timepoint-level aggregate data from studies evaluating weight change after discontinuation of semaglutide or tirzepatide to perform a Bayesian hierarchical longitudinal re-analysis. The model estimated weight loss at cessation…
-
15.
This systematic review and meta-analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow-up. The primary outcome was percentage weight change from baseline. Secondary outcomes included absolute weight change, weight-loss thresholds, HbA1c and safety outcomes. Ten studies including 4…
-
16.
Obesity is a chronic, relapsing disease associated with multiple serious comorbidities. Semaglutide has emerged as an effective pharmacological option for obesity management, owing to its substantial effects on weight loss, cardiometabolic risk factors, and patient-reported outcomes. This systematic review and meta-analysis evaluated the efficacy and safety of subcutaneous semaglutide for weight management in adults with overweight or obesity without diabetes. Randomized controlled trials compar…
-
17.
Despite the recent reports of the potential association between semaglutide and nonarteritic anterior ischemic optic neuropathy (NAION), available evidence remains inconclusive. We aimed to evaluate the relative effect (RE) of NAION in individuals treated with semaglutide compared to the control group. The results of this systematic review and meta-analysis were reported according to the PRISMA guidelines. The study protocol was prospectively registered in PROSPERO with ID: CRD42025649542. A sys…
-
18.
Tirzepatide and semaglutide are widely used for type 2 diabetes mellitus (T2DM) and obesity. However, the blood pressure-related adverse event profiles associated with tirzepatide and semaglutide remain unclear. This study systematically evaluated hypertension- and hypotension-related treatment-emergent adverse events (TEAEs) that occurred when using tirzepatide and semaglutide for the treatment of T2DM or obesity. A comprehensive search was performed in PubMed, Scopus, Web of Science, Embase, C…
-
19.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, are widely used for Type 2 diabetes mellitus (T2DM), obesity and related metabolic conditions. Evidence on potential neuropsychiatric effects remains inconsistent. This systematic review and meta-analysis evaluated depression risk among patients receiving semaglutide. Following PRISMA 2020 guidelines, major biomedical databases, trial registries, pharmacovigilance databases, conference abstracts and grey literature were…
-
20.
The rapid rise in overweight and obesity worldwide underscores the need for comparative evidence on long-term pharmacotherapy. The recent introduction of a 7.2 mg maintenance dose of semaglutide warrants particular attention. We assessed the efficacy and safety of glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists-liraglutide, semaglutide, and tirzepatide-focusing on the incremental value of semaglutide 7.2 mg. We conducted a systematic…
-
21.
Obesity is a chronic multifactorial disease characterized by excess adiposity and persistent low-grade systemic inflammation, contributing substantially to cardiometabolic morbidity and mortality. Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist approved for chronic weight management, promotes weight loss by reducing appetite, delaying gastric emptying, and decreasing energy intake while also demonstrating potential anti-inflammatory effects. Although semaglutide has shown pro…
-
22.
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are leading causes of chronic liver disease worldwide. Despite the rising clinical burden, there are currently no approved pharmacologic therapies. Semaglutide, a glucagon-like peptide-1 receptor agonist with established metabolic and weight-loss benefits, is being evaluated for potential disease-modifying effects in NAFLD/NASH. To assess the efficacy and tolerability of subcutaneous semagluti…
-
23.
Semaglutide and tirzepatide are widely used drugs in the treatment of metabolic diseases based on incretin-based therapy. However, evidence on coronary artery disease (CAD)-related outcomes has largely been derived from separate randomized trials with different control groups, and focused synthesis across CAD phenotypes remains limited. This study aimed to evaluate CAD-related outcomes reported in randomized controlled trials (RCTs) of semaglutide and tirzepatide in adults with type 2 diabetes (…
-
24.
To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients. Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool. Medline, Embase, and Cochrane L…
-
25.
Significant weight gain is a concerning adverse effect of antipsychotic medications experienced by patients with schizophrenia spectrum disorders (SSDs). Its high prevalence and significant contribution to cardiometabolic morbidity in this population warrant better consensus on the management of antipsychotic-induced weight gain and related comorbidity. To evaluate the association between pharmacological interventions and changes in body weight among antipsychotic-treated patients with SSDs. Ovi…
-
26.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in adolescents with overweight or obesity, but their comparative effects on cardiometabolic outcomes across different agents remain uncertain. We aimed to compare the efficacy and safety of different GLP-1RAs on key cardiometabolic parameters in adolescents with overweight or obesity, with or without type 2 diabetes. We searched PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov from inception to…
-
27.
Diabetic retinopathy (DR) is a significant cause of vision impairment in patients with diabetes. The impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the progression of DR remains unclear. This systematic review and meta-analysis aimed to evaluate the association between GLP-1RA therapy and DR progression. A comprehensive search of electronic databases identified 161 records, of which 11 studies met the inclusion criteria. Included studies comprised randomized controlled trials…
-
28.
Obesity-related heart failure with preserved ejection fraction (HFpEF) represents an increasingly prevalent clinical phenotype characterized by exercise intolerance, systemic inflammation, and limited therapeutic options. Semaglutide, a glucagon-like peptide-1 receptor agonist approved for obesity management, has shown favorable effects on symptoms and cardiometabolic markers in patients with HFpEF and obesity, but the overall clinical profile of semaglutide across randomized trials and its rele…
-
29.
Semaglutide, a GLP-1 receptor agonist, has demonstrated metabolic and renal benefits in diabetic populations. However, its efficacy and safety in non-diabetic individuals with obesity and chronic kidney disease (CKD) remain largely unstudied. Given the high cardiometabolic risk in this group and limited therapeutic options, evaluating semaglutide's role is crucial. To assess the effects of semaglutide on body mass index (BMI), blood pressure, renal function (eGFR), and albuminuria in non-diabeti…
-
30.
Chronic kidney disease (CKD) confers substantial cardiovascular and renal morbidity. GLP-1 receptor agonists (GLP-1 RAs) have demonstrated cardiorenal protection across major randomised trials, culminating in the landmark FLOW trial. No prior systematic review has simultaneously synthesised cardiorenal outcomes in a CKD-restricted population, executed a network meta-analysis for agent-level comparisons, or assessed whether SGLT2 inhibitor background therapy modifies treatment effects. MEDLINE, E…
-
31.
The impact of GLP-1 receptor agonists (GLP1-RA) treatment on lean mass and body composition in patients with obesity is not fully understood. Systematic review and meta-analysis of RCTs including patients with obesity treated with GLP1-RA at obesity doses, compared with placebo. Search was conducted in PubMed, Embase, and LILACS in March 2025. A meta-analysis was performed using a random-effects model to evaluate the change in lean mass as a proportion of total weight, the absolute and relative…
-
32.
Long-term weight management drugs have the potential to reduce body weight and blood pressure in obese or overweight individuals. Being overweight or obese is often associated with hypertension, which is linked to an increased risk of cardiovascular mortality and morbidity. The effects of weight-reducing drugs on patient-relevant outcomes, especially in people with hypertension, are currently unclear. This review is the fourth update of one first published in July 2009. Primary objective To asse…
-
33.
The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue. This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population. Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and…
-
34.
Overweight and obesity are global health concerns linked to impaired female fertility. Weight-lowering drugs are an alternative for achieving weight loss; however, their effect on natural female fertility is unclear. A systematic review and meta-analysis were conducted to summarise the literature on the effects of weight-lowering drugs on ovulation, conception, pregnancy and live birth rates. Inclusion criteria comprised interventional and observational studies involving women with overweight or…
-
35.
Semaglutide 2.4 mg causes substantial weight loss, but its average effect on patient-reported physical function requires interpretation against clinically meaningful thresholds and routine clinical expectations. This systematic review and meta-analysis aimed to evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on patient-reported physical functioning and weight-related quality-of-life outcomes in adults with overweight or obesity. In this prospectively registered systematic rev…
-
36.
Overweight and obesity are closely linked to diseases such as type 2 diabetes, coronary heart disease, and stroke and have been shown to increase mortality risk. To conduct a living systematic review of pharmacologic treatments for weight management in overweight or obesity in adults. MEDLINE and Cochrane Central Register of Controlled Trials until October 2025. Randomized controlled trials that compared pharmacologic treatments for weight management (dulaglutide, exenatide, liraglutide, lixisen…
-
37.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are major health burdens. Previous reviews of semaglutide found inconsistent fibrosis improvement. This study aims to provide updated evidence on the efficacy and safety of semaglutide in MASH through a systematic review and meta-analysis. Following PRISMA guidelines (PROSPERO: CRD420261288562), we searched databases through 8 January 2026. Ten studies (n = 1908) were anal…
-
38.
Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk. Tirzepatide, semaglutide, cagrilintide and their combination (CagriSema) have demonstrated efficacy in clinical trials; however, no direct head-to-head studies have compared all advanced ant…
-
39.
The use of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) has expanded dramatically worldwide, with semaglutide being one of the most widely utilized agents. Nonarteritic anterior ischemic optic neuropathy (NAION) has been associated with GLP-1RAs use from emerging pharmacovigilance data. This systematic review and meta-analysis sought to evaluate the risk of NAION in patients with type 2 diabetes mellitus (T2DM). A literature search was made up to September 2025 (PROSPERO: CRD420251155026…
-
40.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated cardiometabolic benefits in randomized controlled trials (RCTs). However, its overall effects on mortality, cardiovascular (CV) and kidney outcomes have not been comprehensively synthesized. This meta-analysis aimed to assess the prognostic impact of semaglutide across the cardio-kidney-metabolic continuum. A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects o…
-
41.
Obesity poses significant challenges for those seeking long-term weight loss through diet and exercise alone. Semaglutide is a GLP-1 receptor agonist approved for chronic weight management in eligible adults. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of semaglutide for treating obesity in adults without diabetes. The protocol was registered in PROSPERO (CRD420261338170). PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were…
-
42.
Hypertension remains a leading contributor to cardiovascular disease globally. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduces blood pressure in clinical trials, but the consistency and magnitude of this effect across populations is unclear. We conducted a systematic review and meta-analysis of placebo-controlled randomized trials reporting blood pressure changes in patients receiving subcutaneous semaglutide. MEDLINE, Web of Science, and Embase were searched through…
-
43.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiometabolic outcomes, but their isolated effects on human bone remodeling remain uncertain because prior syntheses pooled heterogeneous study designs and active antidiabetic comparators. This systematic review and meta-analysis quantified the effects of GLP-1RAs versus placebo on densitometric, biochemical, and inflammatory markers of bone metabolism in randomized controlled trials (RCTs). Scopus, Web of Science, Embase, and PubMed…
-
44.
Cardiovascular death (CVD) remains a leading cause of global mortality. Although semaglutide reduces major adverse cardiovascular events (MACE), the consistency and exact magnitude of its standalone effect on CVD across various patient phenotypes require comprehensive evaluation. This meta-analysis systematically evaluated the clinical efficacy of semaglutide on CVD risk across randomized controlled trials (RCTs). PubMed, Embase, and ClinicalTrials.gov were searched up to July 2026 to identify R…
-
45.
<h4>Background</h4>CagriSema combines cagrilintide with semaglutide and may improve glycaemic control and body weight in Type 2 diabetes. We evaluated its dose- and comparator-specific efficacy and safety.<h4>Methods</h4>PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched through 30 June 2026 for randomized controlled trials. Analyses were stratified by CagriSema dose and comparator. For HbA1c and body weight, efficacy/trial-product estimands were aligned where sufficiently reported, wi…
Systematic Reviews
14-
46.
The aim of this review was to provide all the pharmacokinetic data for semaglutide in humans concerning its pharmacokinetics after subcutaneously and oral applications in healthy and diseased populations, to provide recommendations for clinical use. The PubMed and Embase databases were searched to screen studies associated with the pharmacokinetics of semaglutide. The pharmacokinetic parameters included area under the curve plasma concentrations (AUC), maximal plasma concentration (C Semaglutide…
-
47.
The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. This systematic review aims to assess the incidence of thyroid cancer and detail the spectrum of adverse events associated with semaglutide, focusing on its implications for patient care. Through a sys…
-
48.
The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment. Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglutide and Semaglutide injection monotherapy RCTs until April 2022, using Stata 16 software for Network Meta-Analysis. Twenty-three RCTs study with 11,545 patients and 4 interventions (semaglutide 2.4mg…
-
49.
This study seeks to compare the effectiveness of Semaglutide compared to Liraglutide, Dulaglutide, or Tirzepatide. Additionally, it aims to investigate the implications of transitioning from Dulaglutide or Liraglutide to Semaglutide. We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials. Analyses were conducted us…
-
50.
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained popularity after clinical trials demonstrated their weight-loss potential. The term "Ozempic® face" has been coined to describe the exaggerated volume loss from semaglutide therapy, resulting in advanced facial aging. The authors of this study aim to review plastic surgery publications discussing GLP-1 receptor agonists and characterize the public's perception of the effect of these medications on weight loss. A systematic review of t…
-
51.
<b>Background:</b> Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, which presents with painful nodules, abscesses and sinus tracts. Patients suffer from pain, drainage and worsening of mental health and quality of life. Treatment is often difficult. HS is typically associated with obesity and metabolic syndrome; thus, antidiabetics, especially GLP-1 agonists, present a potential therapy option. The aim of this review was to analyze the effects of GLP-1 agonists on patients…
-
52.
To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs). This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered. A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025. Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semagluti…
-
53.
Incretin-based therapies, including glucagon like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly prescribed for obesity, leading to greater recognition of associated dermatological adverse events (AEs). We aimed to characterize the spectrum, frequency, and clinical characteristics of cutaneous AEs reported with semaglutide, liraglutide and tirzepatide, focusing on these agents because of their established use in both wei…
-
54.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for weight management, yet their skeletal effects remain unclear. This systematic review of eight randomized controlled trials (n = 493) evaluating dual-energy X-ray absorptiometry (DXA)-derived bone mineral density reports findings separately for each agent, without pooling, because the trials evaluated four pharmacologically distinct agents differing markedly in weight-lowering potency. The evidence is sparse for every agent…
- 55.
-
56.
Glucagon-like peptide-1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies. Wernicke's encephalopathy (WE), caused by thiamine deficiency, is a rare but potentially fatal neurological disorder that may result in irreversible cognitive impairment if not promptly recognized and treated. Recently, cases of WE associated with semagl…
-
57.
Although semaglutide is widely used due to its efficacy in glycemic control and weight reduction, cases of the associated adverse drug reactions (ADRs), including kidney injury, have gradually increased. This systematic review aimed to summarize reported cases and case series of semaglutide-associated renal injury and their clinical and laboratory features. Case reports and case series on ADRs associated with semaglutide published in English and Chinese were systematically retrieved using releva…
-
58.
Excessive intrapancreatic fat deposition, also called non-alcoholic fatty pancreas disease, is marked by abnormal fat accumulation in pancreatic tissue and inked to metabolic syndrome, obesity, insulin resistance, and type 2 diabetes mellitus. Despite its clinical importance, intrapancreatic fat deposition lacks standardized diagnostic criteria and is often underdiagnosed. This systematic review explores the pathogenesis, diagnostic challenges, and clinical relevance of intrapancreatic fat depos…
-
59.
<h4>Purpose</h4>To identify and evaluate cardiovascular outcome trials for glucagon-like peptide-1 receptor agonists (GLP1RAs) in various patient populations, including those with or without type 2 diabetes (T2D).<h4>Summary</h4>A systematic search of MEDLINE identified 12 cardiovascular outcome-based randomized controlled trials: 10 in patients with T2D, one in patients with overweight/obesity and atherosclerotic cardiovascular disease (ASCVD) but not T2D, and one in patients with obesity and h…
Practice Guidelines
3-
60.
This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide. FDA-indication and Practice Recommendation: The Wegovy formulation, whose main in…
-
61.
The purpose of this American Gastroenterological Association (AGA) Institute Rapid Clinical Practice Update (CPU) Communication is to review the available evidence and provide expert advice regarding the evolving management of patients taking GLP-1 receptor agonists prior to endoscopy. This CPU was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membe…
-
62.
Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are at risk of cardiometabolic complications and major adverse liver-related outcome (MALO), including cirrhosis, cancer, and liver transplantation. Non-invasive tests (NITs) for hepatic fibrosis, including vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE), or enhanced liver fibrosis (ELF) score, can replace liver biopsy to identify patients at high risk…
Randomised Controlled Trials
50-
63.
Semaglutide 2·4 mg once weekly has been investigated for weight management in global populations. Differences exist between Asian and non-Asian populations in terms of body composition and definitions of obesity. In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus placebo for weight management in adults from east Asia with obesity, with or without type 2 diabetes. This randomised, double-blind, double-dummy, placebo-controlled,…
-
64.
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At…
-
65.
Semaglutide is an effective treatment for type 2 diabetes; however, 20-30% of patients given semaglutide 1·0 mg do not reach glycaemic treatment goals. We aimed to investigate the efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in adults with inadequately controlled type 2 diabetes on a stable dose of metformin with or without a sulfonylurea. We did a 40-week, randomised, active-controlled, parallel-group, double-blind, phase 3B trial (SUSTAIN FORTE) at 125 outpatient clinics…
-
66.
This study evaluated the effect of once-weekly semaglutide 2.4 mg on 2-year control of eating. In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks. A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants. P values were not controlled for multiplicity. In participants completing the Control of Eating Questionnaire (semaglutide, n = 88; placebo, n = 86…
-
67.
Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for once-weekly subcutaneous administration, in development for treatment of type 2 diabetes. We assessed the efficacy and safety of semaglutide versus the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin, thiazolidinediones, or both. We did a 56-week, phase 3a, randomised, double-blind, double-dummy, active-controlled, parallel-group, multinational,…
-
68.
New glucose-lowering medications need to be investigated in east Asian populations, as the clinical characteristics of type 2 diabetes differ between western and east Asian patients. The PIONEER 10 study aimed to evaluate the safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes. PIONEER 10 was an open-label, randomised, active-controlled, phase 3a trial done at 36 sites (clinics and university hospitals) in Japan. Patients aged 20 years and older w…
-
69.
Frailty is common in heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program, semaglutide improved heart failure (HF) symptoms and physical limitations and reduced body weight (BW) in participants with obesity-related HFpEF. Whether the efficacy and safety of semaglutide vary by frailty and the effects of semaglutide on frailty are unknown. This study sought to eva…
-
70.
Once-weekly (OW) subcutaneous (s.c.) semaglutide is an injectable glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. This trial was designed to assess the pharmacokinetics, safety and tolerability of OW s.c. semaglutide in healthy Chinese subjects. In this single-centre, randomised, double-blind, placebo-controlled trial, 36 healthy subjects were randomised to OW s.c. semaglutide 0.5 mg (n = 12), 1.0 mg (n = 12), or placebo (n = 12). Treatment (semaglutide or…
-
71.
Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The safety and pharmacokinetics of oral semaglutide were investigated in two randomised, double-blind, placebo-controlled trials. In a single-dose, first-in-human trial, 135 healthy males received oral semaglutide (2-20 mg semaglutide co-formulated with 150-600 mg SNAC) or placebo with SNAC…
-
72.
We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide 2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL). AE analyses pooled data from the Semaglutide Treatment Effect in People With Obesity (STEP) 1-3 trials for participants randomized to 68 weeks of semaglutide 2.4 mg (n = 2117) or placebo (n = 1262). WL was analysed by presence/absence of GI AEs. Mediation analysis estimated WL effects mediated by and unrelated to GI AEs. GI t…
-
73.
The trial (NCT04016974) investigated the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide, the first orally administered glucagon-like peptide-1 analogue for type 2 diabetes, in healthy Chinese subjects. This single-centre, multiple-dose, placebo-controlled trial randomized 32 healthy Chinese adults to once-daily oral semaglutide (3 mg escalating to 14 mg) or placebo for 12 weeks. Blood samples were collected regularly during treatment and follow-up. The primary en…
- 74.
-
75.
In the Evaluate Renal Function With Semaglutide Once Weekly (FLOW) trial, semaglutide reduced the risk of major kidney and cardiovascular (CV) outcomes and all-cause mortality in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). This prespecified analysis assessed the effects of semaglutide on kidney, CV, and mortality outcomes by baseline mineralocorticoid receptor antagonist (MRA) use. Participants were randomized to once-weekly subcutaneous semaglutide 1.0 mg or placebo. The…
-
76.
Semaglutide and empagliflozin have shown cardiovascular protection. In SUSTAIN-6, semaglutide was associated with an increased risk of diabetic retinopathy. We investigated whether changes in retinal oxygenation, retinal vascular autoregulation, and central retinal thickness are altered by semaglutide, empagliflozin or the combination. This study was a prespecified, secondary outcome from a randomised, 32 weeks partly placebo-controlled, partly open-label, clinical trial on the effects of semagl…
-
77.
Patients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk. This study sought to assess the effect of semaglutide 2.4 mg on all-cause death, CV death, and non-CV death, including subcategories of death and death from coronavirus disease-2019 (COVID-19). The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participan…
-
78.
Prescribing information instructs taking oral semaglutide (a glucagon-like peptide-1 analogue) in the fasting state, followed by a post-dose fasting period of ≥ 30 min. This trial compared the recommended dosing schedule with alternative schedules. This was a randomised, single-centre, multiple-dose, open-label, five-armed, parallel-group trial in healthy subjects who received once-daily oral semaglutide (3 mg for 5 days followed by 7 mg for 5 days). Subjects (n = 156) were randomised to five do…
-
79.
In the Semaglutide Treatment Effect in People with obesity (STEP) trials, once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body weight and improved cardiometabolic parameters in adults with obesity (or overweight with weight-related comorbidities). Effects on the risk of developing type 2 diabetes (T2D) require investigation. STEP 1 (68 weeks) and 5 (104 weeks) randomized participants to semaglutide 2.4 mg or placebo. STEP 4 included a 20-week semaglutide run-in fo…
-
80.
To compare the clinical usefulness of once-weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide at the doses approved for use in Japanese patients with type 2 diabetes. In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial. The primary endpoint was the difference of HbA1c level between the two groups at 24…
-
81.
Oral semaglutide (Rybelsus®) is a co-formulation of semaglutide, a glucagon-like peptide-1 (GLP-1 RA) receptor agonist, with an absorption enhancer, sodium N- (8- [2- hydroxybenzoyl] amino) caprylate (SNAC), which facilitates the absorption of semaglutide across the gastric epithelium in a concentration dependent manner. The safety and efficacy of oral semaglutide were assessed in the PIONEER clinical trial programme, which included 9543 patients with type 2 diabetes (T2DM). Across a range of di…
-
82.
IcoSema is being developed as a subcutaneous once-weekly fixed-ratio combination of the once-weekly basal insulin icodec and the once-weekly glucagon-like peptide-1 receptor agonist semaglutide. This study investigated the pharmacokinetics of icodec and semaglutide in IcoSema versus separate administration of each component in individuals with type 2 diabetes mellitus (T2DM). In a randomised, double-blind, three-period crossover study, 31 individuals with T2DM (18-64 years, body weight 80-120 kg…
-
83.
Explore/exploit decision-making is a crucial component of motivated behavior. Explore/exploit behaviors are related to disparate cognitive and reward-related functions and have been implicated in multiple neuropsychiatric conditions, including major depressive disorder (MDD). Several mediators of explore/exploit decision-making have been proposed; metabolic mechanisms have been theorized to potentially affect its underlying processes. Here, we examined the effects of a GLP-1 receptor agonist (GL…
-
84.
The GLP-1 receptor agonist semaglutide preserves kidney function in people with type 2 diabetes and chronic kidney disease, but the underlying mechanisms are unclear. Here we report a 52-week randomized trial of subcutaneous semaglutide 1 mg once weekly versus placebo (n = 106 (n = 25 women, n = 81 men)) in participants with type 2 diabetes and chronic kidney disease. To identify kidney-specific mechanisms of action for semaglutide, we performed integrated multiparametric magnetic resonance imag…
-
85.
To assess the effect of semaglutide on body composition and physical function. The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m Of 1407 participants, 55 with a valid baseline scan were included (semaglutide 7.2 mg, n = 43, 2.4 mg, n = 6 [pooled semaglutide group, n = 49]; placebo, n = 6). Estimated treatment differences (95% confidence intervals; p-values) for absolute changes in adipose/muscle compartment volumes for the pooled semaglutide versus placebo group, respec…
-
86.
Whether frailty influences the benefit-risk balance of glucagon-like peptide-1 receptor agonists (GLP-1 RA) is uncertain. To evaluate whether frailty modifies the efficacy and safety of the GLP-1 RA semaglutide in adults with cardiovascular disease and overweight/obesity. In this secondary analysis of a randomized clinical trial, participants were adults with a body mass index of 27 or higher and established cardiovascular disease without diabetes. A 31-item frailty index (FI) was constructed us…
-
87.
The endothelium maintains vascular health by regulating blood flow and protecting against inflammatory damage. In type 2 diabetes (T2DM), however, hyperglycemia, hypertension, and hyperlipidemia place a significant burden on the endothelium, potentially leading to atherosclerosis and cardiovascular disease (CVD). While semaglutide and empagliflozin have been shown to reduce CVD risk in T2DM, it remains unclear whether these benefits are mediated by improved endothelial function. This post-hoc an…
-
88.
To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST-T1D randomised controlled trial. Continuous glucose monitoring (CGM) data were collected during a 12-week extension phase after the ADJUST-T1D trial. Analyses included participants previously randomised to semaglutide who discontinued treatment (n = 16) and participants previously randomised to placebo who did not receive a glucagon-like peptide-1 rec…
-
89.
In SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), among 17 604 patients with known atherosclerotic cardiovascular disease and overweight or obesity, but not diabetes, randomization to the glucagon-like peptide-1 receptor agonist semaglutide significantly reduced the primary outcome of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo (mean follow-up, 39.8 mon…
-
90.
Type 2 diabetes drives the progression of metabolic dysfunction-associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium-glucose cotransporter 2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves liver histology in adults with biopsy-proven MASH and type 2 diabetes. In this 52-week, open-label, randomised, parallel-group trial in Japan, adults with biopsy-confirmed MASH and type 2 diabetes received semaglutide plus…
-
91.
Metabolic dysfunction-associated steatohepatitis (MASH) is the progressive form of metabolic dysfunction-associated steatotic liver disease. It is highly prevalent, particularly among individuals with overweight or obesity, and substantially impairs health-related quality of life. Semaglutide 2.4 mg received accelerated approval from the US FDA in August 2025 for adults with noncirrhotic MASH and fibrosis stages F2-F3 based on results from the ESSENCE trial. This study aimed to estimate the impa…
-
92.
Semaglutide 2·4 mg is a GLP-1 receptor agonist that reduces bodyweight, and provides other cardiometabolic benefits, among people with a BMI at least 30 kg/m This completed randomised, double-blind, placebo-controlled, multicentre, two-armed, parallel-group, phase 3b trial (STEP 12) was conducted at 19 sites across mainland China and Taiwan. Adults with a BMI of 24-<28 kg/m Between Sept 15, 2023, and May 7, 2025, of 254 screened participants, 161 (66·5%) of 242 participants were randomly assigne…
-
93.
The GLP-1 receptor agonist semaglutide reduces clinically important kidney outcomes in people with type 2 diabetes and chronic kidney disease (CKD). We aimed to assess the pooled effects of semaglutide on kidney outcomes in prespecified analyses of participant-level data from the diverse populations of the SELECT, FLOW, and SOUL randomised placebo-controlled trials. Participants with CKD (FLOW) or atherosclerotic cardiovascular disease (SELECT and SOUL) were randomly assigned semaglutide (once-w…
-
94.
Accumulating preclinical and observational evidence suggests that glucagon-like peptide-1 receptor agonists, including semaglutide, reduce alcohol consumption. This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD). Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or pla…
-
95.
Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once-weekly semaglutide 2.0 mg as add-on to dose-reduced insulin glargine (Sema+IGlar SUSTAIN OPTIMIZE was a 40-week, phase 3b, open-label, randomised study. Adults with T2D, overweight (body mass index ≥ 25 kg/m Overall, 573 participants were randomised. Sema+IGlar Once-weekly subcutaneous semaglutide 2.0 mg as add-on to dose-reduced IGlar achieved superior reductions in HbA
-
96.
Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin-induced weight gain. Adjunct therapy with modern glucose-lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis. We designed the first Phase 3 clinical trial to assess the efficacy and safety of adding a Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) and a Sodium-Glucose Co-transporter (SGLT2) Inhibitor to…
-
97.
This phase 2 study evaluated once-weekly zalfermin and semaglutide for efficacy and safety in patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, including patients with compensated cirrhosis (F4c). This proof-of-concept, phase 2, dose-ranging, double-blind, randomised controlled trial was done in 187 clinical trial sites in Australia, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Greece, India, Italy, Japan, Malaysia, Poland…
-
98.
To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's national insurance criteria, where obesity is defined as body mass index (BMI) ≥25 kg/m This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum t…
-
99.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide induce rapid weight loss, including facial adipose reduction, which may accelerate sagging due to loss of soft-tissue support. Preventive strategies remain unvalidated, and prospective trials are challenging. To evaluate in silico whether prophylactic injectable treatments along lateral facial vectors mitigate sagging during one year of semaglutide-associated weight loss and compare efficacy across product classes. A large…
-
100.
To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India. A total of 270 patients with body mass index ≥ 30 kg/m Out of 267 randomized patients, 246 completed the study. At Week 24, mean percent weight change from basel…
-
101.
Bofanglutide is a novel glucagon-like peptide-1 receptor agonist under development for type 2 diabetes mellitus (T2DM) and overweight and obesity. To evaluate the efficacy and safety of bofanglutide compared with semaglutide. Phase 2b, randomized, open-label, active-controlled trial. (ClinicalTrials.gov: NCT06256549). Multicenter (37 sites in China). Adults with T2DM who were drug-naive or receiving stable oral antidiabetic drugs (glycated hemoglobin A Participants were randomly assigned 1:1:1:1…
-
102.
Studies of ≤20 wk have demonstrated reductions in energy intake, appetite, and food reward with semaglutide that may drive initial weight loss. These brief studies could not assess whether semaglutide has long-term effects on eating that support the maintenance of lost weight. The goal of the present study was to compare short- and long-term energy intake, appetite, and food reward with semaglutide 2.4 mg to placebo. This 60-wk, double-blind trial randomly assigned 120 adults with overweight/obe…
-
103.
The efficacy of non-invasive ultrasound skin tightening (e.g., Sofwave) relies on fibroblast mechanotransduction, a process impaired in obesity. The widespread use of GLP-1 receptor agonists (GLP-1RAs) like semaglutide for weight loss introduces a dynamic metabolic variable that may further alter dermal tissue state. The optimal timing between these interventions is unknown and difficult to study clinically. We conducted a first fully computational, mechanistically constrained virtual randomized…
-
104.
Treatment with semaglutide compared with placebo for 24 weeks reduced lean body mass and fat mass in adults with CKD and overweight or obesity. Changes in lean body mass or fat mass during semaglutide treatment did not correlate with changes in creatinine or cystatin C‑eGFR or measured GFR. Semaglutide significantly reduced extracellular water and BP, and changes in BP correlated with extracellular water. The glucagon-like peptide-1 receptor agonist semaglutide reduces hemoglobin A1c, body weigh…
-
105.
Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. We aimed to assess the efficacy and safety of cagrilintide-semaglutide for people with type 2 diabetes inadequately controlled with diet and exercise. REIMAGINE 1 was a randomised, double-blind, parallel-group, phase 3a study carried out at 42 sites (study sites included university hospitals, health-care centres, research centres, and ot…
-
106.
The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight. We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overweight or obesity. REIMAGINE 2 was a randomised, double-blind, placebo-controlled and active-controll…
-
107.
Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia. We aimed to compare the efficacy and safety of a once per week combination of cagrilintide with semaglutide (CagriSema) versus placebo as an add-on to basal insulin in individuals with type 2 diabetes. This double-blind, parallel-group, randomised, controlled, phase 3a study (REIMAGINE 3) was done at 46 centres (university hospitals, he…
-
108.
Cardiovascular disease increases risks of chronic kidney disease (CKD) progression and mortality in type 2 diabetes. The study sought to assess semaglutide effects on kidney and survival outcomes by baseline cardiovascular status in the FLOW trial. Participants with type 2 diabetes and CKD were randomized to once-weekly subcutaneous semaglutide 1.0 mg vs placebo. Baseline subgroups included atherosclerotic cardiovascular disease (ASCVD), heart failure, and high total cardiovascular disease risk…
-
109.
Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy. A naïve Bucher ITC was conducted using data from two well-matched randomized controlled trials: OASIS 4 (once-daily oral semaglutide 25 mg vs. placebo) and STEP 1 (once-weekly s.…
-
110.
To evaluate the efficacy, safety and immunogenicity of semaglutide injection (synthetic) (Test group) compared with the Reference semaglutide injection [Ozempic, (Reference group)] in Indian patients with Type 2 diabetes mellitus (T2DM). This Phase III, randomised, open-label, multi-centre, parallel-group, active-controlled non-inferiority study was conducted across 35 centres in India. Adults aged 18-65 years with T2DM and baseline glycated haemoglobin (HbA1c) ≥ 7.0% to ≤ 10.5% despite stable m…
-
111.
This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. In this multicentre, randomised, placebo-controlled and semaglutide-positive-controlled trial, 64 Chinese adults with T2DM were randomly assigned to BGM0504 5 mg (n = 12), 10 mg (n = 12), 15 mg (n = 12), placebo (n = 12) or semaglutide 1 mg (n = 16). All pa…
-
112.
People who smoke cigarettes face increased risk of morbidity and mortality, in part due to elevated rates of cardiometabolic disease. Preclinical and early clinical data indicate that glucagon-like peptide-1 receptor agonists (GLP-1RAs) warrant consideration for smoking cessation and prevention of associated cardiometabolic risks. To evaluate the effects of semaglutide vs placebo on cigarette smoking, craving, and weight outcomes in people who smoke. This parallel-arm phase 2a randomized clinica…
Clinical Trials
5- 113.
-
114.
Human immunodeficiency virus (HIV)-associated lipohypertrophy is characterized by excess central and visceral adiposity and is associated with increased cardiometabolic risk among people with HIV (PWH). In a previously reported randomized trial, semaglutide significantly reduced body weight, regional adiposity, and insulin resistance over 32 weeks of active treatment. However, the durability of these benefits after treatment discontinuation is unknown. We conducted a randomized, placebo-controll…
-
115.
Semaglutide is approved in Chile for the management of type 2 diabetes mellitus (T2DM), although it is generally not available in the public health system. Generating local evidence may aid in its incorporation into national guidelines and reduce the therapeutic gap with international standards. To evaluate the effectiveness and safety of adding weekly semaglutide to the standard treatment for T2DM in the public health system. A phase 4, multicenter, interventional study evaluated the weekly add…
-
116.
We have shown that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is a highly effective therapy for metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV (PWH). The OWLiver® metabolomics algorithms allow non-invasive MASLD severity staging without liver biopsy, but the use of metabolomic data for disease monitoring with GLP-1RA therapy has not been reported. SLIM LIVER (ACTG A5371) was an open-label, phase 2b, single-arm trial of semaglutide in P…
-
117.
To investigate the efficacy and safety of intensifying once-weekly insulin icodec (icodec) with once-weekly semaglutide in adults with type 2 diabetes (T2D). ONWARDS 8 was a single-arm, open-label, treat-to-target, Phase 3b trial comprising a 26-week icodec run-in period and a 26-week semaglutide intensification period. Eligible participants were adults with T2D (glycated haemoglobin [HbA1c]: 7.5%-10.5%) receiving daily basal insulin but not receiving a glucagon-like peptide-1 receptor agonist.…
Trial Registrations (ClinicalTrials.gov)
297- 118.
-
119.
Conditions: Coronary Artery Disease, PreDiabetes
-
120.
Conditions: Obesity and Overweight, Appetite Regulation
-
121.
Conditions: Diabetes Mellitus, Type 2
- 122.
-
123.
Conditions: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2 (+1)
-
124.
Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1
-
125.
Conditions: Overweight, Obesity
-
126.
Conditions: Obesity, Body Weight Changes
-
127.
Conditions: Diabetes, Diabetes Mellitus, Type 2
-
128.
Conditions: Weight Management
-
129.
Conditions: Diabetes Mellitus, Type 2
-
130.
Conditions: Obesity, Weight Loss
-
131.
Conditions: Obesity and Overweight
-
132.
Conditions: Psoriasis (PsO), Obesity and Overweight
-
133.
Conditions: Type 2 Diabetes Mellitus
- 134.
- 135.
-
136.
Conditions: Diabetes, Diabetes Mellitus, Type 2
-
137.
Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
-
138.
Conditions: Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
- 139.
-
140.
Conditions: Diabetes Mellitus, Type 2
-
141.
Conditions: Metabolic Disease, Obesity & Overweight
-
142.
Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy
-
143.
Conditions: Diabetes Mellitus, Type 2
-
144.
Conditions: Pharmacokinetics, Safety Issues, Bioequivalence
-
145.
Conditions: Obesity (Disorder), Weight Change, Blood Pressure Monitoring (+1)
-
146.
Conditions: Cognitive Change
-
147.
Conditions: Gastric Retention
- 148.
- 149.
-
150.
Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
-
151.
Conditions: Type 1 Diabetes
-
152.
Conditions: Polycystic Ovary Syndrome
- 153.
-
154.
Conditions: Psoriasis Arthritis
-
155.
Conditions: Hyperglycemia, Renal Transplant Complication Primary Non-Function, Diabetes
-
156.
Conditions: Diabetes Mellitus, Obesity
-
157.
Conditions: Overweight, Obesity
-
158.
Conditions: Non-alcoholic Fatty Liver Disease
- 159.
-
160.
Conditions: Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease
-
161.
Conditions: Type 2 Diabetes
-
162.
Conditions: Diabetes, Diabetes Mellitus, Type 2
-
163.
Conditions: Diabetes Mellitus, Type 2
-
164.
Conditions: Diabetes Mellitus, Type 2
-
165.
Conditions: Overweight and Obesity, Type2diabetes
-
166.
Conditions: Methamphetamine-dependence
-
167.
Conditions: Obesity, Chronic Kidney Disease, Chronic Renal Disease (+1)
-
168.
Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
-
169.
Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease
- 170.
-
171.
Conditions: Valid MeSH Conditiongs
-
172.
Conditions: Alzheimer Disease, Diabetes Mellitus Type 2, Obesity & Overweight
- 173.
-
174.
Conditions: Type 2 Diabetes Mellitus (T2DM)
-
175.
Conditions: Obesity & Overweight, Cardiometabolic Health Indicators, Addiction (+2)
- 176.
-
177.
Conditions: Obesity
-
178.
Conditions: Obesity &Amp; Overweight
-
179.
Conditions: Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence
-
180.
Conditions: Kidney Transplant Recipient
-
181.
Conditions: Morbid Obesity
-
182.
Conditions: Obesity & Overweight, Mobility Disability, HOMA-IR
-
183.
Conditions: Obesity & Overweight
-
184.
Conditions: Early Alzheimer´s Disease
-
185.
Conditions: Obesity
-
186.
Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions (+1)
-
187.
Conditions: Duchenne Muscular Dystrophy (DMD)
- 188.
-
189.
Conditions: Breast Cancer (Early Breast Cancer), Obesity
-
190.
Conditions: Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing (+1)
-
191.
Conditions: Obesity, Skeletal Muscle, Brain Connectivity
- 192.
- 193.
- 194.
-
195.
Conditions: Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I (+6)
-
196.
Conditions: Pulmonary Arterial Hypertension
-
197.
Conditions: Atrial Fibrillation (AF), Obesity & Overweight
-
198.
Conditions: Obesity
- 199.
-
200.
Conditions: Obesity
-
201.
Conditions: Non-alcoholic Steatohepatitis
-
202.
Conditions: Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM
-
203.
Conditions: Obesity, Adolescent
-
204.
Conditions: Overweight, Obesity, Type 2 Diabetes
-
205.
Conditions: Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
-
206.
Conditions: Pediatric Obesity, Obesity
-
207.
Conditions: Overweight, Obesity
-
208.
Conditions: Diabetes type1, Obesity
-
209.
Conditions: Chronic Kidney Diseases, Obesity
-
210.
Conditions: Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis (+1)
-
211.
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
-
212.
Conditions: HIV, Alcohol, Smoking Cigarette (+1)
-
213.
Conditions: Type 2 Diabetes Mellitus
-
214.
Conditions: Type 2 Diabetes, Cardiovascular Disease, Omega-3 Fatty Acids
-
215.
Conditions: Schizophrenia Spectrum Disorders
-
216.
Conditions: Class I/II Obesity
-
217.
Conditions: Heart Failure, Heart Valve Prosthesis
-
218.
Conditions: Endometrioid Endometrial Adenocarcinoma
-
219.
Conditions: Obesity
-
220.
Conditions: Chronic Kidney Diseases, MAFLD
- 221.
- 222.
-
223.
Conditions: Type 2 Diabetes (T2DM)
- 224.
-
225.
Conditions: Type 2 Diabetes Mellitus (T2DM)
-
226.
Conditions: Type 1 Diabetes Mellitus
-
227.
Conditions: Morbid Obesity
-
228.
Conditions: Obesity & Overweight
-
229.
Conditions: Obesity/Therapy
- 230.
-
231.
Conditions: Obesity & Overweight, Type 2 Diabetes
-
232.
Conditions: Type 2 Diabetes, Heart Failure
-
233.
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- 234.
-
235.
Conditions: Obesity and Overweight, Obese Adolescents, Weight Management (+2)
-
236.
Conditions: Type 2 Diabetes
- 237.
- 238.
-
239.
Conditions: Obesity & Overweight
-
240.
Conditions: Obesity & Overweight, Diabetes (DM)
-
241.
Conditions: Overweight, Obesity
-
242.
Conditions: Arthritis, Obesity & Overweight, GLP - 1
-
243.
Conditions: Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk (+1)
-
244.
Conditions: Cocaine Use Disorder, HIV
-
245.
Conditions: Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder (+2)
- 246.
-
247.
Conditions: Childhood Obesity, Treatment Adherence
-
248.
Conditions: Acute Myocardial Infarction With ST Elevation
-
249.
Conditions: Obesity & Overweight
-
250.
Conditions: Intracerebral Hemorrhage
-
251.
Conditions: Heart Failure With Reduced Ejection Fraction, Obesity, Weight Loss (+1)
-
252.
Conditions: Obesity, Diabetes Type 2
- 253.
- 254.
-
255.
Conditions: Heart Failure With Preserved Ejection Fraction, Obesity, Diastolic Heart Failure (+2)
-
256.
Conditions: Cerebral Small Vessel Disease
-
257.
Conditions: Atrial Fibrillation, Obesity, Weight Loss
-
258.
Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
-
259.
Conditions: Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I (+3)
-
260.
Conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory (+3)
- 261.
-
262.
Conditions: Chronic Kidney Disease, Type 2 Diabetes
-
263.
Conditions: Spinal Cord Injuries, Type 2 Diabetes
-
264.
Conditions: Type 2 Diabetes Mellitus (T2DM)
- 265.
-
266.
Conditions: Diabetes Mellitus, Type 2
- 267.
-
268.
Conditions: Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain (+2)
- 269.
-
270.
Conditions: Healthy Aging
- 271.
-
272.
Conditions: Overweight, Obesity
-
273.
Conditions: Diabetes Mellitus, Type 2
-
274.
Conditions: Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain (+1)
-
275.
Conditions: Methamphetamine Use Disorder
- 276.
-
277.
Conditions: Type 2 Diabetes (T2DM)
-
278.
Conditions: Chronic Kidney Disease
-
279.
Conditions: Obesity; Chronic Kidney Disease; Albuminuria
-
280.
Conditions: Type 2 Diabetes, Obesity
-
281.
Conditions: Obesity / Overweight
-
282.
Conditions: Obesity, Overweight, Cigarette Smoking
-
283.
Conditions: Diabetes Mellitus, Type 2
-
284.
Conditions: Obesity (Disorder), Anti-obesity Agents, Precision Medicine
-
285.
Conditions: Obesity, Childhood
- 286.
-
287.
Conditions: Obesity
-
288.
Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH) (+2)
- 289.
-
290.
Conditions: Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
-
291.
Conditions: Obesity, Childhood
-
292.
Conditions: Post-Bariatric Hypoglycemia
-
293.
Conditions: Obesity, Overweight
-
294.
Conditions: Diabetes Mellitus, Insulin Sensitivity
-
295.
Conditions: Obesity &Amp; Overweight, Digestive Disorders
- 296.
-
297.
Conditions: Type 2 Diabetes, Overweight, ASCVD
-
298.
Conditions: Obesity, Metabolic Syndrome, Brown Adipose Tissue
-
299.
Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity (+1)
-
300.
Conditions: Type 1 Diabetes, Overweight , Obesity
-
301.
Conditions: Kidney Disease, Chronic, Diabetes, Dialysis (+1)
-
302.
Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders (+4)
- 303.
-
304.
Conditions: Obesity, Obese, Overweight or Obesity
-
305.
Conditions: Ischemic Stroke
-
306.
Conditions: Diabetes Mellitus, Type 2
-
307.
Conditions: Type 2 Diabetes Mellitus, Obesity, Overweight
-
308.
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Conditions: Diabetes Mellitus, Type 2
-
309.
Conditions: Food Addiction Tendency, Obesity, Overweight
-
310.
Conditions: Obesity & Overweight, Weight Loss, Preventative Health (+2)
- 311.
- 312.
-
313.
Conditions: Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
-
314.
Conditions: Overweight, Obesity
- 315.
-
316.
Conditions: Prostate Cancer
- 317.
-
318.
Conditions: Alcohol Use Disorder
-
319.
Conditions: Double Diabetes
- 320.
-
321.
Conditions: Diabetes Mellitus, Type 2
-
322.
Conditions: Diabetes Mellitus, Type 2
- 323.
-
324.
Conditions: Obesity
- 325.
-
326.
Conditions: Diabetes Mellitus, Type 2
-
327.
Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
- 328.
-
329.
Conditions: Caloric Restriction, Body Composition, Performance
-
330.
Conditions: Steroid-Induced Diabetes, Steroid Induced Hyperglycemia
-
331.
Conditions: Osteoarthritis (OA) of the Knee
- 332.
-
333.
Conditions: Cardiovascular Events, Type2 Diabetes, Renal Disease
-
334.
Conditions: Steatosis of Liver, Metabolic Liver Injury, Obesity (+2)
-
335.
Conditions: Diabetes Mellitus Type 2
-
336.
Conditions: Adult Obesity, Weight Management
-
337.
Conditions: Diabetes Mellitus, Type 2
-
338.
Conditions: Type 2 Diabetes, Cognitive Decline in Older Adults
-
339.
Conditions: Glucose Intolerance After a Recent History of Gestational Diabetes
-
340.
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
- 341.
-
342.
Conditions: Adiposity, Fatty Liver, Alcohol Use Disorder
-
343.
Conditions: Obesity, Chronic Kidney Disease
-
344.
Conditions: Addiction, Alcohol Use Disorder
- 345.
- 346.
-
347.
Conditions: Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)
-
348.
Conditions: Obesity, Sarcopenia
-
349.
Conditions: Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
-
350.
Conditions: Overweight and/or Obesity
-
351.
Conditions: Autism Spectrum Disorder, Obesity
-
352.
Conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma
-
353.
Conditions: Obesity, Overweight and/or Obesity, Overweight (+1)
-
354.
Conditions: Alzheimer Dementia (AD)
-
355.
Conditions: Chronic Kidney Diseases
- 356.
-
357.
Conditions: Type 2 Diabetes Mellitus (T2DM)
-
358.
Conditions: HIV/AIDS, Lipohypertrophy, Obesity
-
359.
Conditions: Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
-
360.
Conditions: Cardiovascular Risk, Chronic Kidney Disease
-
361.
Conditions: Endometrial Cancer, Atypical Hyperplasia, Fertility Perservation
-
362.
Conditions: Cardiovascular Disease
- 363.
-
364.
Conditions: Overweight, Obesity
- 365.
-
366.
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome
-
367.
Conditions: Overweight, Obesity
-
368.
Conditions: Type 1 Diabetes Mellitus
-
369.
Conditions: Short Bowel Syndrome (SBS), Intestinal Failure
-
370.
Conditions: Early Alzheimer's Disease
-
371.
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
-
372.
Conditions: Overweight, Obesity
-
373.
Conditions: Obesity, Overweight
-
374.
Conditions: Obesity & Overweight
- 375.
-
376.
Conditions: Cannabis Use Disorder, Cue-reactivity
-
377.
Conditions: Overweight, Obesity
-
378.
Conditions: Lactation, Weight Loss
-
379.
Conditions: Type 2 Diabetes, Osteopenia
-
380.
Conditions: Caloric Restriction, Body Composition, Performance
- 381.
-
382.
Conditions: Bioequivalence, Pharmacokinetics
-
383.
Conditions: Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
-
384.
Conditions: Obesity (Disorder), GLP-1 Receptor Agonist Treatment, Probiotic Intervention (+1)
-
385.
Conditions: Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
- 386.
-
387.
Conditions: Obesity
-
388.
Conditions: Diabetes Mellitus, Type 1
- 389.
-
390.
Conditions: Obesity, Diabetes, Metabolic Syndrome
-
391.
Conditions: Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
-
392.
Conditions: Obesity and Obesity-related Medical Conditions
-
393.
Conditions: Type 2 Diabetes Mellitus, Obesity
-
394.
Conditions: GLP-1 Receptor Agonist Treatment
-
395.
Conditions: Prostate Cancer
-
396.
Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
-
397.
Conditions: Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
-
398.
Conditions: Diabetes Mellitus, Type 2
- 399.
-
400.
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
-
401.
Conditions: Polycystic Ovary Syndrome (PCOS) Women, Obesity
- 402.
-
403.
Conditions: Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- 404.
-
405.
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
-
406.
Conditions: Aging, Functional Decline
-
407.
Conditions: Obese Diabetics, Obese Non Diabetic
-
408.
Conditions: Opioid Use Disorder
-
409.
Conditions: Non-diabetec Obesity, Obesity (Disorder)
-
410.
Conditions: Diabetes Mellitus, Type 2
-
411.
Conditions: Obesity, Menopause
-
412.
Conditions: Type 2 Diabetes Mellitus (T2DM)
-
413.
Conditions: Obesity (Disorder)
- 414.
Reviews
36-
415.
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTA…
-
416.
Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabete…
-
417.
Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic
-
418.
Glucagon-like peptide-1 receptor agonists (GLP-1As) are being used as approved or off-label treatments for weight loss. As such, there has been increasing concern about the potential for GLP-1As to impact eating disorder (ED) symptomatology. This article seeks to (1) review the current state of knowledge regarding GLP-1As and ED symptomatology; (2) provide recommendations for future research; and (3) guide ED clinicians in how to discuss GLP-1As in clinical practice. Although evidence is limited…
-
419.
Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use. This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications for emergency clinicians. GLP-1 agonists potentiate insulin release and reduce gastric emptying and food intake. These agents have demonstrated significant improvements in glucose control in diabetics a…
-
420.
Recently, two oral-administered peptide pharmaceuticals, semaglutide and octreotide, have been developed and are considered as a breakthrough in peptide and protein drug delivery system development. In 2019, the Food and Drug Administration (FDA) approved an oral dosage form of semaglutide developed by Novo Nordisk (Rybelsus
-
421.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that modulates glucose metabolism and insulin secretion. Recent translational and clinical research has evaluated the effects of GLP-1 receptor agonists (GLP-1 RAs), a class of drugs that mimic the action of native GLP-1 in the central nervous system (CNS). In addition to the efficacy of GLP-1 for the treatment of diabetes mellitus and obesity, preliminary evidence indicates GLP-1s have neuroprotective, therapeutic, and disease modification…
-
422.
Oral semaglutide (Rybelsus
-
423.
Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and re…
-
424.
Obesity is a global health concern, necessitating effective weight-loss interventions. This study aimed to compare the efficacy and safety of semaglutide, a pharmacotherapeutic option, with bariatric surgery, a commonly utilized surgical intervention, for weight reduction. A systematic review of clinical trials, including the STEP (Semaglutide Treatment Effect in People) trials, sustain trials, pioneer trials, and the STAMPEDE (Surgical Treatment and Medications Potentially Eradicate Diabetes Ef…
- 425.
-
426.
GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns have arisen about their potential link to thyroid cancer. This study investigates the association between thyroid cancer and weight-loss medications. A disproportionality analysis was conducted using data from the FDA Adverse Event Reporting System (FAERS) from 2004 to Q1 2024. Reporting odds ratios (RORs) were used to identify associations bet…
-
427.
It is critical for individuals with type 2 diabetes mellitus (T2DM) to maintain optimal glycemia while avoiding hypoglycemia, control body weight, and reduce cardiovascular risk. The GLP-1 receptor agonists stimulate glucose-dependent insulin release (low risk of hypoglycemia), inhibit glucagon secretion, slow gastric emptying and suppress appetite (weight loss). The new members of the class are available as once daily or weekly injections. Additionally, some members of the class have demonstrat…
-
428.
Previously, the only available glucagon-like peptide-1 receptor agonists (GLP-1 RA) were injectable. Approval of oral semaglutide (Rybelsus®) represents the first orally available GLP-1 RA. To review the literature and describe pharmacologic, pharmacokinetic, and pharmacodynamics properties; clinical safety; and efficacy of oral semaglutide, a newly approved oral GLP-1 RA. A MEDLINE (1995-October 2019) and ClinicalTrials.gov search was conducted using the terms oral semaglutide, semaglutide, PIO…
- 429.
-
430.
Semaglutide (▼Ozempic solution for injection, ▼Rybelsus tablets-Novo Nordisk) was initially granted market authorisation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In 2021 and 2022, regulatory agencies in the USA and Europe licensed semaglutide (▼Wegovy solution for injection-Novo Nordisk) for the treatment of individuals who are obese, or overweight and who have at least one weight-related comorbidity. Manufacturer-sponsored randomised controlled trials have shown…
-
431.
Obesity is a chronic disease with significant global health repercussions. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) are now established as evidence-based options for long-term obesity management. This review compares semaglutide and tirzepatide aims to support precise, equitable, and durable care for people with the disease of obesity. This review provides clinicians with a comparative analysis of semaglutide (Ozempic) and tirzepatide (Mounjaro) in o…
-
432.
Semaglutide (Ozempic®), administered as a weekly subcutaneous injection up to 1.0 mg, holds a privileged place in the international guidelines for the management of type 2 diabetes. Commercialized under the trade name Wegovy®, semaglutide is also indicated at a weekly dose up to 2.4 mg for the management of obesity or over-weight with at least one weight-related comorbidity, after failure and in combination with life-style interventions. Its efficacy and tolerance were investigated in the STEP c…
-
433.
This review assessed the selected information on semaglutide's activity, its potential for the treatment of various diseases, and its pharmacokinetics. It is intended as a guide for future research. Chromatographic procedures used for the determination of semaglutide in various biological samples were also reviewed. A comprehensive review of the literature was conducted by searching scientific databases including PubMed, Scopus, Web of Science, and Google Scholar. The search was performed using…
-
434.
Obesity remains a critical global health issue with profound medical and economic implications. While injectable medications such as semaglutide (Wegovy®) and tirzepatide (Zepbound®) have demonstrated significant efficacy, the development of novel oral anti-obesity agents presents additional therapeutic potential. This narrative review examines recent advances in oral pharmacotherapy for obesity, focusing on mechanisms of action, clinical effectiveness, anticipated benefits and side effects. A s…
-
435.
Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basali…
-
436.
The present article discusses the evaluation and surgical planning of body contouring procedures for weight loss patients. These patients require thorough preoperative evaluation and patient education. Distinction should be made between massive weight loss and moderate medication-assisted weight loss (MMA) as these patient populations are managed differently and there are unique preoperative considerations with the MMA population. Given that weight loss patients often have multiple concerns, com…
-
437.
Cardiovascular disease mortality rates, which had steadily declined over decades, are now plateauing or reversing due to the global rise in type 2 diabetes mellitus (T2DM) and obesity. These cardiometabolic conditions contribute significantly to atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease. Among emerging pharmacological treatments, glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown benefits beyond diabetes and obesit…
-
438.
This opinion paper aims to discuss the influence of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on lean mass beyond its impact on weight loss. Although significant weight loss is achieved with semaglutide, the impact of this drug on lean mass remains controversial. Several investigations have demonstrated that semaglutide-induced weight loss is linked to decreases in lean mass as well as fat mass; on the other hand, the ratio of lean mass to total body mass rises. Neverthe…
-
439.
Obesity has been described by the WHO as the largest health threat facing mankind. More than 55% of pregnancies in the United Kingdom occur in women who are overweight or living with obesity. Obesity in pregnancy increases the risk of developing gestational diabetes mellitus (GDM), a condition that affects one in seven pregnancies globally and is associated with short- and long-term risks for both mother and baby. Therefore, optimising treatment to effectively treat both obesity and GDM in the p…
-
440.
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a long elimination half-life, allowing subcutaneous (sc) administration once per week. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) recently approved once-weekly sc semaglutide for the treatment of type 2 diabetes mellitus (T2DM). The weight loss efficacy of once-weekly sc semaglutide appears to be superior compared with the other once-weekly GLP-1 RAs in patients with T2DM. Semagluti…
- 441.
-
442.
T2DM (type 2 diabetes mellitus) is a chronic and progressive illness with high morbidity and death rates. Oral semaglutide (Rybelsus®) is a combination of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and sodium N- (8- [2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that facilitates semaglutide absorption across the gastric epithelium in a concentration-dependent manner. This family of drugs apart from glucose lowering effects causes significant weight lo…
-
443.
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO). Although GLP-1 might enhance bone metabolism and quality, the impact of these receptor agonists on bone health remains uncertain and is the subject of this review. Data on bone health in the context of calorie restriction and…
-
444.
The purpose of this review paper is to review the efficacy and safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon-like peptide-1 receptor agonist for obesity management. A MEDLINE search (1970 to June 2021) was conducted to identify Phase 3 trials of subcutaneous semaglutide for obesity management. Published Phase 3 trials from The Semaglutide Treatment Effect in People with obesity (STEP) program were reviewed and summarized. Based on four Phase 3 trials, subcutaneous semaglutid…
-
445.
This article is intended as a brief review on the glucagon-like peptide-1 (GLP-1) agonist Semaglutide (Ozempic®, Rybelsus®, Wegovy®), an antidiabetic medication that has gained significant popularity in the United States for its role in long-term weight-loss management. While current research on GLP-1 agonists, including semaglutide, focuses primarily on their therapeutic effects in managing diabetes and obesity, information regarding their forensic and medicolegal significance is limited. Conce…
-
446.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent and severe liver disease globally, encompassing a spectrum from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory form that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The multifaceted pathogenesis of MASH, particularly in the setting of obesity and type 2 diabetes mellitus (T2DM), has resulted in the exploration of pharmaca that targ…
-
447.
Overweight and obesity are major global health challenges and key drivers of cardiovascular disease (CVD), yet patients with established CVD and excess body weight remain systematically under-recognized and undertreated. This consensus paper, developed by an Italian multidisciplinary panel of cardiology, endocrinology and obesity experts, aims to characterize the clinical phenotype of CVD patients most likely to benefit from semaglutide therapy, identify barriers to its implementation, and propo…
-
448.
To compare the safety and tolerability profiles of oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) against established injectable peptide GLP-1RAs, with emphasis on orforglipron, the most clinically advanced class member. This narrative review synthesises receptor pharmacology, Phase 3 clinical trial data, network meta-analyses, and regulatory prescribing-information documents for orforglipron; early-phase data for GSBR-1290 and CT-996 are considered separately as hypoth…
-
449.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, lowers high-sensitivity C-reactive protein (hsCRP) by 29-55% across randomised trials in obesity, heart failure with preserved ejection fraction and obstructive sleep apnoea, and interleukin-6 by 25-30% at 72 weeks. Much of this is not weight-mediated: in SURPASS-4 the fall in hsCRP correlated with that in body mass index at r = 0.07, and mediation analysis of trials of se…
-
450.
Peripheral artery disease (PAD) may be the most frequent first manifestation of cardiovascular disease (CVD) in type 2 diabetes (T2D). Management of PAD in T2D aims to improve symptoms and lower the high risk of major adverse cardiovascular (MACE) and limb (MALE) events. Drugs commonly used are lipid-lowering and antihypertensive medicines, antithrombotic and antihyperglycemic agents. The ADA recommends both GLP-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2…
Research Articles
162-
451.
Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic preclinical studies suggest weight loss is mediated through GLP-1 receptors (GLP-1Rs) in the brain. The findings presented here show that semaglutide modulated food preference, reduced food intake, and caused weight loss without decreasing energy expenditure. Semaglutide directly accessed the brainstem, septal nucleus, and hypot…
-
452.
New patients turning to semaglutide (Ozempic® and Wegovy®), a glucagon-like-peptide 1 (GLP-1) agonist, for weight loss, have captivated social media platforms. Wegovy® carries a United States (US) Food and Drug Administration (FDA) approval for chronic weight management in patients who have a body mass index (BMI) 27 kg/m2 or greater and at least one weight-related condition (eg, hypertension, type 2 diabetes, cholesterol) or in patients with a 30 kg/m2 or greater BMI. Although…
- 453.
- 454.
-
455.
Doxorubicin is a powerful chemotherapeutic agent for cancer, whose use is limited due to its potential cardiotoxicity. Semaglutide (SEMA), a novel analog of glucagon-like peptide-1 (GLP-1), has received widespread attention for the treatment of diabetes. However, increasing evidence has highlighted its potential therapeutic benefits on cardiac function. Therefore, the objective of this study was to examine the efficacy of semaglutide in ameliorating doxorubicin-induced cardiotoxicity. Doxorubici…
-
456.
Obesity is a growing global health concern, leading to various health issues, including diabetes. Semaglutide-based medications, such as Ozempic, Wegovy, and Rybelsus, have emerged as potential treatments. These medications, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, mimic the action of GLP-1, regulating appetite and promoting weight loss. Clinical trials have shown their effectiveness in reducing body weight and improving metabolic parameters. Ozempic, though Food…
-
457.
Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market. Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most commonly to treat type II diabetes. To date, the results of semaglutide for the treatment of type II diabetes have been overwhelmingly positive. It is for the drug's effects on appetite suppression and weight loss, however, that have led its surge in popul…
-
458.
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD). Here, we examined the effects of semaglutide, a long-acting GLP-1 analogue, on biobehavioral correlates of alcohol use in rodents. A drinking-in-the-dark procedure was used to test the effects of semaglutide on binge-like drinking in male and female mice. We also tested the effects of se…
-
459.
Type 2 Diabetes Mellitus therapy has evolved over the years to now include a new class of therapeutics, semaglutide. This article reviews the mechanism of action and formulation of semaglutide therapy, potential benefits, contraindications, adverse effects, and drug interactions. Oral and subcutaneous semaglutide therapies have shown effectiveness in improving glycemic control, weight loss, and reducing cardiovascular risks associated with diabetes mellitus. Semaglutide has also shown potential…
-
460.
Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD). However, the probability of low semaglutide doses, an agonist with higher potency and affinity for GLP-1R, to attenuate alcohol-related responses in rodents and the underlying neuronal mechanisms is unknown. In the intermittent access model, we examined the ability of semaglutide to decrease alcohol intake and block relapse-like drinking…
-
461.
Obesity and diabetes of different types are considered global health risks with rising prevalence. In addition to low-calorie diet and daily exercise, several treatment options have been introduced to help patient in needs. Semaglutide (Ozempic) is one popular agent, which attracted the attention of both physicians and patients due to its positive outcome in improving glucose control and weight loss. However, no reports on the effect of semaglutide use on the oral cavity and specifically xerosto…
- 462.
-
463.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease associated with type 2 diabetes mellitus (T2D). NAFLD can progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and even cancer, all of which have a very poor prognosis. Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, has been recognized as a specific drug for the treatment of diabetes. In this study, we used a gene mutation mouse model (db/db mice) to investigate the potential liver-improving…
-
464.
Glucagon-like peptide 1 (GLP-1) agonists are a drug class used for the treatment of diabetes that have recently gained FDA approval for medical management of obesity. The off-label use of Ozempic (Novo Nordisk, Bagsværd, Denmark), the brand name of the GLP-1 agonist semaglutide, for cosmetic weight loss has been popularized by social media and celebrity influence. The aim of this study was to analyze with Google Trends (Alphabet Inc., Mountain View, CA) the recent search popularity of Ozempic an…
-
465.
Recent Food and Drug Administration approvals of glucagon-like peptide 1 (GLP-1) receptor agonists linked to substantial weight loss have generated interest in demand projections. However, a longitudinal analysis in a large, diverse, current, real-world database has not been published. The study objective was to determine user frequency of GLP-1 receptor agonist products overall and by type 2 diabetes (T2D), cardiovascular disease (CVD), and overweight or obese status. Secondary objective was mo…
-
466.
In 2014, the US Food and Drug Administration approved the first glucagon-like peptide-1 (GLP-1) receptor agonist product, liraglutide injection, for obesity treatment. Many GLP-1 obesity treatment clinical trials report significant weight loss and medication adherence at more than 85%. Little is known about the real-world GLP-1 obesity treatment adherence, persistence, and switch rates. To measure GLP-1 therapy persistence, adherence, and switch rates in a real-world cohort of members without di…
-
467.
A surge in the use of semaglutide injection (Ozempic Nationwide population-based cross-sectional study based on linked health registries January 2018 through December 2023. All adults who received a first prescription of semaglutide once weekly (Ozempic The new user rate of semaglutide (Ozempic The use of semaglutide (Ozempic
-
468.
Semaglutide is a human glucagon-like peptide-1 analogue in clinical development for the treatment of type 2 diabetes. The absorption, metabolism and excretion of a single 0.5mg/450μCi [16.7MBq] subcutaneous dose of [
-
469.
In recent years, semaglutide has repeatedly attracted attention in the press and on social media due to its effects in weight management. The social media hype led to off-label use and global supply shortages. Our goal was to identify differences in the presentation of semaglutide on individual social media platforms. Additionally, we aim to investigate the mentioning of various aspects such as adverse drug reactions, drug indications, supply shortages, and costs. Current social media trends reg…
-
470.
Recent studies have suggested an association between nonarteritic anterior ischemic optic neuropathy (NAION) with semaglutide usage. However, the limitations of those analyses warrant further investigation, given the frequency of use of these medications in people with and without diabetes. To investigate the association between semaglutide use and the risk of NAION among patients with diabetes. This cohort study used data from the TriNetX database between October 1, 2019, and December 31, 2023,…
-
471.
The use of the GLP-1R agonist semaglutide is revolutionizing the treatment of obesity, yet its mechanistic effects on energy balance remain elusive. Here, we demonstrate that reactivation of semaglutide-responsive dorsal vagal complex neurons mimics the drug's effects of reducing food intake and body weight and promoting fat utilization and conditioned taste aversion. We observe that many of the semaglutide-activated area postrema (AP) and nucleus of the solitary tract (NTS) neurons express Adcy…
-
472.
Glucagon-like peptide-1 receptor agonists improve glycaemic control: some are now available as oral and subcutaneous formulations, and some have indications for reducing cardiovascular risk. The expanded scope for these therapies warrants comprehensive safety evaluations. We report the safety/tolerability of subcutaneous and oral semaglutide from the SUSTAIN and PIONEER clinical trial programmes, respectively. Adverse events (AEs) from 16 randomized placebo- or active-controlled phase IIIa trial…
-
473.
Postpartum mothers and their healthcare providers often face the challenge of limited data regarding the safety of drug therapies during lactation. Pregnancy can lead to sustained weight gain, and obesity can negatively impact both physical and psychological well-being. The introduction of GLP-1 agonists to augment weight loss has become a topic of interest for many postpartum mothers. Our study aims to investigate the transmission of semaglutide into human milk in the first steps to ensure the…
-
474.
To investigate the therapeutic effects and mechanisms of Semaglutide in Alzheimer's disease (AD), and identify its potential targets. We systematically evaluated the effect of Semaglutide on Alzheimer's disease (AD), using both mice and human organoid models. Behavioral analyses on APP/PS1 mice demonstrated that Semaglutide improved the cognitive capabilities, particularly in the learning and memory domains. Biochemical investigations further highlighted its role in reducing amyloid plaque depos…
-
475.
To determine patient characteristics and dose titration patterns of real-world semaglutide (Wegovy) users. We used a population-based cohort study including Danish adults who filled semaglutide prescriptions from 12 December 2022 to 31 December 2023. Outcomes were patient characteristics, prescriber type, and dose titration patterns. We identified 110,748 individuals (median age 49 years; 70% female) filling 773,708 prescriptions for semaglutide. General practitioners initiated treatment in 86%.…
-
476.
The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D), on the bioavailability of a combined oral contraceptive was investigated. Postmenopausal women with T2D (n = 43) on diet/exercise ± metformin received ethinylestradiol (0.03 mg)/levonorgestrel (0.15 mg) once daily for 8 days before (semaglutide-free) and during (steady-state 1.0 mg) semaglutide treatment (subcutaneous once weekly; dose escalation: 0.25 mg 4 weeks; 0.5 m…
-
477.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert cardiovascular benefits in diabetic patients, but the underlying mechanisms remain incompletely understood. Semaglutide, a novel long-acting GLP-1RA, has shown a reduced risk of cardiovascular events. Based on these results, we investigated the therapeutic potential of semaglutide in diabetic cardiomyopathy and sought to elucidate the underlying mechanisms. Mice with diabetes induced by high-fat diet/streptozotocin were treated with sema…
-
478.
Systemic and cerebral inflammatory responses are implicated in the pathogenesis of obesity and associated metabolic impairment. While the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome has been linked to obesity-associated inflammation, whether it contributes to the development or maintenance of obesity is unknown. We provide support for a direct role of saturated fatty acids, such as palmitic acid, as NLRP3 activating stimuli in obese states. To investigate whether NLRP3…
-
479.
In order to investigate whether a central nervous system penetrant anti-inflammatory could augment or sustain obesity treatment with semaglutide (Wegovy), a glucagon-like peptide-1 receptor (GLP-1R) agonist, we tested two hypotheses in models of diet-induced obesity (DIO): 1) a centrally penetrant NLPR3 inhibitor, NT-0796, drives enhanced weight loss when combined with low-dose semaglutide, compared to monotherapy; and 2) NT-0796 monotherapy sustains weight loss induced by semaglutide. Mice fed…
-
480.
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide and others) now promises effective, non-invasive treatment of obesity for individuals with and without diabetes. Social media platforms' users started promoting semaglutide/Ozempic as a weight-loss treatment, and the associated increase in demand has contributed to an ongoing worldwide shortage of the drug associated with levels of non-prescribed semaglutide intake. Furthermore, recent reports emphasized some GLP-…
-
481.
Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. Topiramate is also commonly prescribed off-label for binge eating but has many contraindications. In contrast, the glucagon-like peptide-1 (GLP1) analog semaglutide has profound effects on central satiety signaling leading to reduced food intake, and has been approved for the treatment of obesity based on its efficacy and safety pr…
-
482.
Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist known to delay gastric emptying. Despite a growing body of evidence, its peri-operative safety profile remains uncertain, particularly with regard to the risk of increased residual gastric content and aspiration of gastric contents during anaesthesia. We hypothesised that semaglutide interruption of ≤ 10 days before elective surgical procedures is insufficient to reduce or normalise the residual gastric content, despite fastin…
-
483.
Withdrawal of semaglutide is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. There are some studies implying that metformin might attenuate weight regain. The weight trajectory after discontinuation of short-term semaglutide treatment in obese women with PCOS who continued metformin treatment has not yet been evaluated. We explored changes in body weight, cardiometabolic and endocrine parameters in obese women wit…
-
484.
With the increasing use of GLP-1 receptor agonist (GLP-1 RA) drugs for weight loss and diabetes management, concerns have been raised regarding their potential side effects. We aim to assess the frequency of otolaryngologic adverse events (AEs). Retrospective analysis of national registry. The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year…
- 485.
-
486.
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound), are widely used for the treatment of type 2 diabetes mellitus (T2DM) and obesity. While these agents are well known for their metabolic benefits, there is growing interest in their potential effects on cancer biology.…
-
487.
The use of glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide, a novel class of antidiabetic medications, has raised concerns about potential adverse effects, particularly a possible association with thyroid cancer (TC). This study aims to evaluate whether semaglutide influences the progression of TC by modulating tumor-associated macrophages (TAMs). Semaglutide was administered to human papillary thyroid carcinoma (PTC) xenograft mouse models, coculture systems consisting of…
-
488.
The glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved as an oral formulation for the treatment of type 2 diabetes. This study aimed to confirm bioequivalence between a new, second-generation (2G) oral semaglutide formulation (1.5, 4 and 9 mg) and the initially approved first-generation (1G) formulation (3, 7 and 14 mg). This was a randomised, multicentre, open-label, full replicate crossover study to confirm bioequivalence between 2G and 1G oral semaglutide formulations at steady-…
-
489.
Semaglutide is a GLP-1 receptor agonist that is highly efficacious in reducing food intake and body weight. While semaglutide reduces adipose tissue, there is also a loss of lean mass including skeletal muscle, though it is unclear whether this translates to a loss of muscle function. The effect of discontinuation of semaglutide on rebound weight gain and shifts in body composition is also not well understood. We investigated the impact of semaglutide and matched caloric restriction on body comp…
- 490.
- 491.
-
492.
Facial plastic surgeons report seeing an increase in patients presenting with facial deflation and a prematurely aged appearance-a reported side effect of the weight-loss drug semaglutide. No objective data exist to quantitatively characterize midface volume loss in these patients. Retrospective cohort study. Single, tertiary academic medical center. Hospital-level electronic medical record data were systematically queried for patients with glucagon-like peptide-1 (GLP-1) agonist prescriptions a…
-
493.
Ozempic (semaglutide) was first authorized to treat type 2 diabetes, but because of its appetite-suppressing properties, it has become popular off-label for weight loss. According to clinical investigations, GLP-1 significantly decreases blood sugar and helps people lose weight. Approximately 15 million persons in the United States are currently taking GLP-1 drugs. Off-label use is becoming more common, which raises worries about potential health hazards and significant side effects such as non-…
-
494.
Diabetes-associated cognitive decline (DACD), characterized by cognitive impairment, is a serious complication of diabetes mellitus (DM). Research has shown that semaglutide, a novel glucagon-like peptide-1 receptor agonist, has neurotrophic and neuroprotective properties. However, a comprehensive understanding of the specific effects and underlying mechanisms of semaglutide treatment in patients with DACD remains lacking. In this study, we evaluated the potential of semaglutide to alleviate DAC…
-
495.
Semaglutide 2.4 mg injection (Wegovy This retrospective cohort study included adults with overweight or obesity and ≥ 1 pharmacy claim for semaglutide 2.4 mg or tirzepatide in the US Komodo Health database between June 4, 2021, and December 15, 2023. Patients had continuous enrollment for 1 year before (baseline period) and 1 year after (follow-up period) the index date (date of treatment initiation) and persistence on therapy (no gap of > 30 days' supply) during follow-up. Patients with T2DM at…
-
496.
To evaluate the effectiveness of semaglutide 2.4 mg for weight reduction and improvement in cardiometabolic biomarkers at 52 and 68 weeks in a real-world setting in the United States. This noninterventional, retrospective cohort study used the Komodo Health database and included adults with obesity or overweight with ≥1 weight-related condition who initiated treatment with semaglutide 2.4 mg between June 2021 and August 2022 and remained on treatment for 1 year. A paired t-test was used to asses…
-
497.
With the prevalence of obesity rising in the US, medical management is of increasing importance. Two popular options for the treatment of obesity are bariatric surgery (e.g. sleeve gastrectomy and Roux-en-Y gastric bypass) and the increasingly popular GLP-1 Receptor Agonists (GLP-1 s). This study examines the initial and long-term costs of GLP-1 s compared to bariatric surgery. We compared average 2023 national retail prices for GLP-1 s to surgical cost estimates from 2015 adjusted for inflation…
-
498.
Glucagon-like peptide 1 receptor agonists (e.g. semaglutide) potently induce weight loss and thereby reducing obesity-related complications. However, weight regain occurs when treatment is discontinued. An increase in skeletal muscle oxidative phosphorylation (OXPHOS) efficiency upon diet-mediated weight loss has been described, which may contribute to reduced systemic energy expenditure and weight regain. We set out to determine the unknown effect of semaglutide on muscle OXPHOS efficiency. C57…
- 499.
-
500.
The recent endorsement of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy), by the American College of Cardiology as first-line therapy for weight management marks a paradigm shift in cardiometabolic care. Semaglutide offers significant benefits, including improved glycemic control and substantial weight loss, with emerging data demonstrating its impact even in individuals without diabetes. However, GLP-1 receptor agonists' growing popularity raises important conce…
-
501.
Glucagon-like peptide 1 receptor agonists have shown promising results in obesity treatment. In France, semaglutide 2.4-mg (Wegovy) has benefited from an early-access program from July 2022 to September 2023. This study aimed to describe the user profile of semaglutide 2.4-mg and the dosage patterns under real-world conditions during this period. Between July 2022 and September 2023, semaglutide 2.4-mg initiators were identified through the nationwide APMO database (Accès Précoce-Médicaments Oné…
-
502.
To investigate weight loss outcomes of semaglutide in a real-world setting, specifically in patients who have undergone metabolic/bariatric surgery (MBS). Despite excellent weight loss for semaglutide in clinical trials, actual results may be limited due to factors such as costs, drug availability, insurance coverage, and adverse events. A retrospective series of patients with obesity prescribed semaglutide at a large multidisciplinary weight management center in a tertiary academic institution.…
- 503.
-
504.
Semaglutide, available widely as Ozempic, Wegovy, and Rybelsus, has significantly improved the management of type 2 diabetes and obesity due to its beneficial adverse drug reactions and safer use in diverse population. However, as its use grows widely, rare but serious side effects are coming to light. One such emerging concern is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a condition causing sudden, often irreversible vision loss. A retrospective, post-market observational study…
-
505.
Obesity, a chronic disease with escalating global prevalence, poses considerable health risks. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have demonstrated efficacy for weight loss in clinical trials. The paradigm shift in the approach to obesity management drugs (OMDs) may offer an opportunity to examine online search activity and prescription trends. To investigate prescription patterns and online search trends for OMD and correla…
-
506.
Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes.
Type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction, which significantly impacts the quality of life. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown potential neuroprotective effects. This study investigates the efficacy of semaglutide in ameliorating cognitive dysfunction in a mouse model of T2DM. Male C57BL/6J mice were fed a high-fat diet for four weeks and received a single intraperitoneal injection of streptozotocin (150 mg/kg) to induce T2DM…
-
507.
In recent years, there has been a dramatic increase in the popularity and use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. As such, it is essential to understand users' real-world discussions of short-term, long-term, and co-occurrent adverse events associated with currently used GLP-1 RA medications. This study aims to quantitatively analyze temporal and co-occurrent GLP-1 RA adverse event trends through discussions of GLP-1 RA weight loss medications on Facebook fr…
- 508.
-
509.
Obesity-induced inflammation and oxidative stress can cause damage to cardiomyocytes. Semaglutide has the potential to reduce glucose levels and weight, while hydroxysteroid dehydrogenase-like protein 2 (HSDL2) also plays a role in regulating lipid metabolism. This study aimed to investigate the expression of oxidative stress markers and HSDL2 in myocardium and serum under high-fat conditions, in order to elucidate the mechanism of obesity-induced myocardial injury and evaluate the impact of sem…
-
510.
The purpose of this study was to explore how semaglutide, a GLP-1RA, regulates serum metabolism and gut microbiota to improve obesity in mice and whether fecal microbiota transplantation (FMT) can transmit the beneficial effects of semaglutide to recipient mice. Male C57BL/6J mice were given standard diet (ND), high-fat diet (HFD), or high-fat diet with semaglutide (SHF, 100 μg/kg). Fecal microbiota transplantation was used to transplant the fecal suspension supernatant (MT) and bacteria (FMT) f…
-
511.
Semaglutide, a glucagon-like peptide 1 receptor agonist, is an antidiabetic that has recently shown promising immunomodulatory and antitumor effects. Breast cancer is the most common type of cancer affecting women worldwide. The aim of this study was to analyze the effects of semaglutide on the antitumor immunity in a 4T1 mouse breast cancer model. After induction of breast cancer, BALB/C mice were treated intraperitoneally with semaglutide. Semaglutide administration decelerated tumor appearanc…
-
512.
Semaglutide (Ozempic, Wegovy) has surged in popularity for its weight loss effects. Its widespread media coverage may have an outsized impact on adolescents and young adults due to their higher engagement in social media and their vulnerability to unintended consequences of weight-related discourse (e.g., body dissatisfaction, disordered eating, weight stigma). This study aimed to determine youth familiarity with and opinions about use of medications such as Ozempic and Wegovy for weight loss. F…
-
513.
A growing number of studies show that the diabetes drug Semaglutide is neuroprotective in Alzheimer's disease (AD) animal models, but its mode of action is not fully understood. In order to explore the mechanism of Semaglutide, 7-month-old APP/PS1/tau transgenic (3xTg) mice and wild-type (WT) mice were randomly divided into four groups: control group (WT + PBS), AD model group (3xTg + PBS), Semaglutide control group (WT + Semaglutide) and Semaglutide treatment group (3xTg + Semaglutide). Semaglu…
-
514.
Obesity and its cardiovascular complications are major causes of morbidity and mortality. Little is known in real-world settings about the effect of newly approved antiobesity medications (AOMs) on cardiovascular complications among patients with obesity. This retrospective cohort study examined the association between newly approved AOM use and cardiovascular events among Medicare patients with obesity using data from 2020 to 2022. Patient age, gender, comorbidity scores, socioeconomic status,…
-
515.
This cross-sectional study examined associations between self-reported taste perception changes and appetite-related outcomes in individuals with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RAS) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAS in real-world conditions. Four hundred and eleven adults on Wegovy® (n = 217), Ozempic® (n = 148) and Mounjaro® (n = 46) completed an online survey assessing sociodemographic, anthropometric and sensory changes…
- 516.
- 517.
-
518.
Semaglutide is a once-weekly GLP-1 receptor agonist that has been proposed as a gerotherapeutic, yet no data exist on its effects on epigenetic aging. We therefore conducted a post-hoc epigenetic analysis of a 32-week, double-blind, placebo-controlled phase 2b trial in adults with HIV-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). Paired peripheral-blood methylomes were profiled to evaluate semaglutide's impact across multiple generations of DNA-methylation clocks. After adjust…
- 519.
- 520.
-
521.
To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management. This retrospective analysis utilized the Healthcare Integrated Research Database® to identify adults with T2D starting tirzepatide or injectable semaglutide between May 13, 2022 and May 29, 2023.…
- 522.
-
523.
Semaglutide was not detectable in the milk of mothers taking the drug subcutaneously. Their breastfed infants experienced no adverse effects. Some brands of oral semaglutide, such as Rybelsus, contain the absorption enhancer salcaprozate sodium, which may enter milk and accumulate in infants. Only injectable forms of semaglutide should be used during breastfeeding.
-
524.
<h4>Background</h4>Prescription drug list prices in the United States far exceed those in peer nations, averaging 278% of non-US prices and 422% for branded products. The Inflation Reduction Act authorized Medicare to negotiate net prices for high-expenditure drugs, resulting in maximum fair prices (MFPs) for 15 Part D products effective in 2027. Subsequently, Centers for Medicare and Medicaid Services (CMS) introduced the GLOBE and GUARD models, which propose a most-favored nation (MFN) pricing…
-
525.
<h4>Background</h4>Novel glucagon-like peptide-1 receptor agonists (GLP1RAs) for obesity treatment have generated considerable dialogue on digital media platforms. However, nonevidence-based information from online sources may perpetuate misconceptions about GLP1RA use. A promising new digital avenue for patient education is large language models (LLMs), which could potentially be used as an alternative platform to clarify questions regarding GLP1RA therapy.<h4>Objective</h4>This study aimed to…
-
526.
Semaglutide, marketed as Ozempic, Wegovy and Rybelsus, has rapidly become one of the most prominent medications of recent years. Initially approved in 2021 for type 2 diabetes in adults, semaglutide is now authorised for obesity management in adults and children in several countries, including Germany, the UK, Denmark and the United Arab Emirates. Despite this broad regulatory approval, its paediatric use remains a subject of debate. Advocates highlight its potential to reduce cardiovascular ris…
-
527.
In late 2025, the White House announced new Most Favored Nation (MFN) pricing agreements for the glucagon-like peptide-1 receptor agonist class, including 3 semaglutide products, establishing substantially lower prices for Medicare and Medicaid. Shortly after, the Centers for Medicare and Medicaid Services released Maximum Fair Prices (MFPs) for selected drugs under IPAY 2027, revealing semaglutide prices that differed from the MFN prices and from earlier assumptions used in prior economic evalu…
-
528.
Semaglutide (Ozempic, Rybelsus, Wegovy) is a GLP-1 receptor agonist used for the treatment of type 2 diabetes and, more recently, weight management. Due to its efficacy in weight loss, semaglutide has gained worldwide popularity, particularly the branded version Ozempic, resulting in off-label use by people seeking rapid weight loss. The resulting high demand has led to an increase in falsified products sold by unregulated online marketplaces. We present a case of a 31-year-old woman who was adm…
-
529.
<h4>Objective</h4>To evaluate two-year costs to insured patients treated with Roux-en-Y gastric bypass (RYGB) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes (T2D) and obesity.<h4>Methods</h4>Using the 2017 to 2023 Merative™ claims database, we identified adult patients with severe obesity and T2D who were treated with a RYGB or GLP-1 RAs. Patients with RYGB had no treatment with GLP-1 RAs, and those who received GLP-1 RAs therapy with tirzepatide or semaglutide for…
-
530.
Prescriptions made for GLP-1 agonists under various brand names (e.g., Ozempic, Wegovy) have more than tripled since 2020. However, research on their use and their side effects at the population level is in its infancy. This study presents descriptive findings from a 2025 survey fielded to a nationally representative sample of U.S. adults as part of RAND's American Life Panel that show prevalence rates of GLP-1 agonist use and side effects.
- 531.
-
532.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135 349 individuals treated with semaglutide and tirzepatide formulations and stratified them as "super responders" (>15% weight loss), "moderate responders" (5%-15% weight loss), "minimal weight-loss group" (<5% weight loss), and "weight regainers." Ozempic, Wegovy, Mounjaro, and Zepbound had si…
- 533.
-
534.
<h4>Background and aims</h4>The rising global prevalence of obesity has catalyzed the development of potent glucagon-like peptide-1 (GLP-1) receptor agonists. This narrative review evaluates the efficacy, safety, and practical considerations of injectable semaglutide for weight management, specifically in non-diabetic adults, a population where weight loss outcomes often differ from those seen in diabetic cohorts.<h4>Methods</h4>Using information from PubMed, Scopus, and Web of Science, a themat…
-
535.
Glucagon-like peptide-1 (GLP-1), an incretin hormone, plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and delaying gastric emptying. Its therapeutic potential was long realized, leading to the development of the first GLP-1 receptor agonist, exenatide, followed by liraglutide, dulaglutide, semaglutide, and tirzepatide. Semaglutide is available as a weekly subcutaneous injection with high bioavailability. Semaglutide is the only GLP-1 ag…
-
536.
Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse Event Reporting System (2017-2024), we evaluated formulation- and sex-specific associations. Among 31 774 semaglutide cases, Wegovy demonstrated the strongest signal for ION (reporting odds ratio (ROR)=74.89) compared with Ozempic (ROR=18.81). Sex-stratified analyses showed higher odds in men (ROR=1…
- 537.
- 538.
-
539.
Obesity is a global health issue that impacts millions of people worldwide. Semaglutide is a glucagon-like peptide-1 receptor agonist that was initially developed as a treatment for type 2 diabetes mellitus under the brand name Ozempic. Additional studies showed semaglutide at larger doses (marketed as Wegovy) to be an effective medication for weight management. Wegovy for managing obesity is typically well tolerated; however, there have been reports of gastrointestinal adverse effects. Only 1 c…
- 540.
-
541.
Räsänen and Ahola-Launonen recently offered a commentary on an ethical analysis I co-authored with Julian Savulescu on the use of semaglutide-based weight-loss drugs such as Ozempic. In this response, I continue the discussion by engaging their concerns about the narrow framing of our analysis with respect to the structural determinants of health and the conditions of autonomy, as well as the role of race, class and gender in shaping stigma and access to treatment. I argue that Räsänen and Ahola…
-
542.
<h4>Background</h4>Psoriatic disease (PsD) is a chronic systemic inflammatory condition associated with significant cardiometabolic comorbidities, including obesity, type 2 diabetes mellitus (T2DM), and cardiovascular (CV) disease. These comorbidities are interlinked via shared immunopathogenic mechanisms, notably chronic low-grade inflammation driven by Th1/Th17 cytokines such as TNF, IL-6, and IL-17. Obesity, in particular, exacerbates PsD severity and treatment resistance, underscoring the ne…
- 543.
-
544.
<h4>Background</h4>Social media has been extensively used by the public to seek information and share views on health issues. Recently, the proper and off-label use of semaglutide drugs for weight loss has attracted huge media attention and led to temporary supply shortages.<h4>Objective</h4>The aim of this study was to perform a content analysis on English YouTube (Google) videos related to semaglutide.<h4>Methods</h4>YouTube was searched with the words semaglutide, Ozempic, Wegovy, and Rybelsu…
-
545.
<b>Objectives</b>: This study aimed to assess the prevalence and patterns of GLP-1 receptor agonist (GLP-1 RA) use for weight loss and to identify factors associated with their use among overweight and obese adults in the Eastern Province of Saudi Arabia. <b>Methods</b>: A cross-sectional study was conducted among overweight and obese adults aged 18 years and older residing in the Eastern Province. Data were collected in December 2024 using an online, self-administered questionnaire. Descriptive…
-
546.
<h4>Aims</h4>To examine the impact of FDA approval of semaglutide (Wegovy) for chronic weight management on the utilization gap between males and females in the United States.<h4>Materials and methods</h4>The study utilized 2019-2024 MarketScan commercial claims data. Changes in the GLP-1RA utilization 30 months before and 31 months after the US FDA's approval of semaglutide (Wegovy) for chronic weight management in June 2021 were evaluated using segmented regression of interrupted time series.…
-
547.
Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has attracted significant global attention for its appetite-suppressing and weight-loss effects. Approved for pediatric use in children aged 12 and older, Wegovy has been described as a "miracle drug" and hailed as a potential solution to the so-called "obesity epidemic." However, prescribing medication to children raises complex ethical questions, including how best to respect y…
- 548.
-
549.
Semaglutide (Wegovy), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has attracted global attention for its appetite-suppressing and weight-loss effects. Approved by the U.S. FDA in 2022 for adolescents aged 12 and older, it has since been authorized in several other countries. Despite this, its use among youth remains limited, with ongoing concerns about its long-term safety, efficacy, and suitability during periods of growth and development. Advocates see Wegovy as an important tool fo…
-
550.
<b>Background:</b> Metabolic dysfunction-associated steatosis liver disease (MASLD), formerly termed nonalcoholic fatty liver disease (NAFLD), has emerged as the most prevalent cause of chronic liver disease worldwide. For decades, the absence of approved pharmacological therapies has hindered effective clinical management, leaving lifestyle modification and sustained weight reduction as the only recommended interventions. Yet, achieving and maintaining clinically meaningful weight loss remains…
-
551.
Bile acid diarrhea (BAD) is a chronic and socially debilitating disease characterized by abdominal pain, diarrhea, urgency, and fecal incontinence. Recently, in a 6-week randomized controlled trial, we showed that the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide is superior to bile acid sequestration (considered standard-of-care) using colesevelam in reducing BAD symptoms. The emergence of new, more potent, and longer-acting GLP-1RAs has spurred an interest in these treatments…
-
552.
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for inducing weight loss has increased in recent years, resulting in a parallel reduction in demand for bariatric surgery. Consequently, the need for patients to undergo aesthetic procedures, including aesthetic breast surgery, following successful GLP-1 RA-induced weight loss is expected to increase while the demand created by postsurgical weight loss is expected to decrease. The objective of this narrative review is to examine th…
-
553.
<h4>Background</h4>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasing in prevalence as the "go-to" medication for type 2 diabetes, obesity, and off-label weight loss. The changes associated with the use of these medications can result in an undesirable change in facial structure and skin quality, leading to a more aged appearance in users of these medications. This study aimed to identify whether increased public interest in these GLP-1RA-related face changes, a phenomenon terme…
-
554.
<h4>Background</h4>This study aimed to assess the prevalence of glucagon-like peptide-1 (GLP-1) receptor agonist use and interest in using medications for weight loss among adults (≥ 18 years) in Great Britain.<h4>Methods</h4>Nationally representative household survey, January-March 2025 (n = 5893). Participants were asked whether they had used medication in the past year to manage type 2 diabetes (excluding insulin), reduce the risk of heart disease, or support weight loss and, if so, whether t…
-
555.
<h4>Background</h4>On or before November 1, 2025, the Centers for Medicare & Medicaid Services (CMS) will report the agreed-upon negotiated prices (maximum fair prices [MFPs]) for the second round of up to 15 Medicare Part D drugs selected for price negotiation (Initial Price Applicability Year 2027).<h4>Objective</h4>To propose guideline-recommended therapeutic alternatives and estimate price benchmarks that may be considered by CMS for negotiation.<h4>Methods</h4>We identified US Food and Drug…
-
556.
<h4>Purpose</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained considerable media attention, but there is limited knowledge about those receiving the drugs. This study aimed to assess demographic characteristics and previous diagnoses in patients dispensed GLP-1 RAs in Region Stockholm, Sweden, between 2019 and 2023, with a focus on off-label prescribing.<h4>Methods</h4>This was a register-based cross-sectional study including all inhabitants in Region Stockholm, Sweden, who w…
-
557.
<h4>Background</h4>Off-label use of semaglutide as Ozempic<sup>®</sup> for weight loss has surged in the Arab populations in the absence of structured real-world evaluation.<h4>Objective</h4>To assess utilization patterns, effectiveness, and patient satisfaction with off-label Ozempic use for weight reduction across Arab populations.<h4>Methods</h4>A cross-sectional survey was conducted using a validated bilingual questionnaire. Data included demographics, source of initiation, dose escalation,…
- 558.
-
559.
<h4>Background</h4>User experience has a significant impact on pharmaceutical drug effectiveness. Social media platforms like X (formerly Twitter) have become prominent spaces where individuals share their medication-related experiences, especially with widely marketed drugs such as semaglutide. Despite the large volume of conversation, a comprehensive understanding of how various user subpopulations engage with semaglutide-related discussions remains underdeveloped.<h4>Objective</h4>This study…
-
560.
<h4>Background</h4>Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently raised concerns about its ocular safety. This study aimed to investigate the association between semaglutide use and vision impairment using data from the FDA Adverse Event Reporting System (FAERS).<h4>Methods</h4>We conducted an analysis of FAERS data, comparing reports of vision impairment associated with semaglutide to those associated with other antidiabetic and weight los…
- 561.
-
562.
<h4>Background</h4>Clinical obesity is a prevalent chronic disease, significantly increasing morbidity and mortality while impairing quality of life. As diet and physical activity interventions often prove ineffective in the long term, with increasing use of pharmacotherapy, drug shortages and injection aversion present a challenge. The role of oral semaglutide at a dose of 14 mg (registered for type 2 diabetes) as a treatment for obesity in patients without diabetes remains undefined.<h4>Method…
-
563.
Semaglutide is a glucagon-like peptide 1 (GLP-1) agonist that has found widespread popularity as a weight loss product. Initially developed as a treatment for diabetes, the drug acts to stimulate the secretion of insulin, as well as suppress appetite by delaying gastric emptying and promoting satiety. By allowing users to moderate their weight, the drug may provide a competitive advantage to those individuals participating in sports that are regulated by weight classes, such as wrestling and box…
-
564.
GLP-1 and its synthetic analogs have emerged as significant therapeutic agents for the management of metabolic disorders, merging glycemic control with weight loss through innovative structural and delivery breakthroughs. This review provides a meticulous exploration of GLP-1, elucidating its origin, secretion, and the challenges associated with its clinical application due to its fragility in the presence of DPP-IV, resulting in a short half-life. To overcome this limitation, various modificati…
-
565.
Obesity is a major public health challenge in the United States, despite widespread implementation of regulated diet plans, exercise programs, behavioral interventions, and surgical procedures. The emergence of incretin-based therapies, particularly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists, has transformed the therapeutic landscape for initially type 2 diabetes and now obesity. Beyond their metabolic effects, incretin therapies exer…
-
566.
The aim of this narrative review is to critically assess the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing albuminuria among patients with type 2 diabetes mellitus within the framework of personalized medicine. By integrating current evidence from clinical trials and meta-analyses, the review highlights how GLP-1RAs not only enhance glycemic control but also reduce blood pressure, induce weight loss, and mitigate inflammatory responses. While these gi…
-
567.
Purpose The purpose of this study was to assess aspiration risk in patients undergoing elective eye surgery with moderate sedation as the anesthetic while taking the glucagon-like peptide type 1 receptor agonist (GLP-1RA) Ozempic formulation of semaglutide. Setting and design This retrospective observational study took place in Fleming Island Surgery Center and East West Surgery Center, Fleming Island, Florida. Methods Records of patients actively taking the Ozempic formulation of semaglutide an…
- 568.
-
569.
Oral delivery of peptides and proteins has been pursued for over a century due to its noninvasive nature. Despite sustained innovation across multiple technological generations-such as enteric coatings, enzyme inhibitors, permeation enhancers, nanoparticles, and ingestible devices-most oral peptide programs have failed to achieve regulatory or commercial success. The recent approval of oral semaglutide has renewed enthusiasm but introduced a substantial risk of conceptual over-extrapolation. Thi…
- 570.
-
571.
<h4>Background</h4>This study systematically compares the risk of long-term ocular adverse events between subcutaneous and oral semaglutide preparations to assess pathway-specific safety differences.<h4>Methods</h4>In this study, the Report odds ratio (ROR) technique was employed to detect signals of adverse drug reactions (ADRs) associated with the use of semaglutide. Analysis was conducted on data extracted from the FDA Adverse Event Reporting System (FAERS) database, covering the period from…
- 572.
-
573.
Currently, GLP-1RAs are peptide drugs, typically administered by injection due to insufficient absorption, and only one GLP-1RA, semaglutide, is available as an orally administered drug. To overcome the absorption challenges of oral peptides, this drug product contains the absorption enhancer SNAC. As the tablet is eroded in the stomach, SNAC neutralizes the acidic gastric environment, thereby protecting the semaglutide from enzymatic degradation. Then, SNAC fluidizes the stomach lipidic membran…
-
574.
Obesity management is complex; medications must be used in conjunction with behavioural changes and monitoring by health professionals. Injectable drugs for weight management include glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. liraglutide, semaglutide) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (e.g. tirzepatide). These drugs contribute to weight loss by mimicking the incretin hormones GLP-1 and GIP to reduce appetite, change food enjoyment, s…
-
575.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight. Agents such as dulaglutide, liraglutide, semaglutide, and tirzepatide differ in pharmacology and dosing, directly influencing perioperative safety, particularly due to their effects on gastric motility and the high frequency of gastrointestinal (GI) adverse events that raise concerns about aspiration and postoperative morbidity in urgent or elective procedu…
-
576.
Purpose Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an increasingly prevalent class of drugs for managing overweight/obesity and type 2 diabetes mellitus. Postmarket surveillance is essential for characterizing their risk profiles in real-world patient populations as clinical use increases. This study investigated the association of GLP-1RAs with mortality and serious adverse events (AEs) reported to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Meth…
- 577.
- 578.
- 579.
-
580.
In the fall of 2024, a U.S. Senate Hearing on the high price of Novo Nordisk's prescription drugs Ozempic and Wegovy underlined some of the deepest challenges in the U.S. health care system. This article utilizes critical approaches to both political economy and sociological discussions of medicalization as a means to address these challenges. Market-led organization and medicalization underlie not only these products' pricing, but also wider issues of cost control and health care organization.…
-
581.
Menopause is associated with visceral obesity, low-grade chronic inflammation, and increased risk of dyslipidemia, insulin resistance, and type 2 diabetes. Although exercise (EXE) and GLP-1 receptor agonists, such as semaglutide (SEM), have demonstrated beneficial effects on metabolic regulation, their combined impact in menopause models has been less investigated. In this study, ovariectomized female Wistar rats were divided into four experimental groups: sedentary plus saline (SED + SAL), sede…
-
582.
It is often reported that people with schizophrenia experience weight gain and disordered eating, partly due to antipsychotics. As part of the RCT "Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes, HISTORI", the present study investigates experiences of hunger and eating habits in people using antipsychotics during semaglutide treatment. Eleven semi-structured interviews were conducted 4 months to 1,5 years after treatment completion. Six women and 5 men were…
-
583.
Burn injury-induced pain (BIP) is a complex condition whose spinal mechanisms remain incompletely understood. Although spinal glucagon-like peptide-1 receptor (GLP-1R) signaling has been implicated in pain modulation, its contribution to BIP remains unclear. Using a mouse model of second-degree burn injury, we characterized nociceptive behaviors, spinal glial responses, and the temporal and cellular distribution of GLP-1R using immunoblotting, immunofluorescence, and RNAscope in situ hybridizati…
-
584.
Semaglutide, a member of the glucagon-like peptide-1 receptor agonists, induces substantial weight loss, primarily through appetite suppression and reduced energy intake. In addition to fat mass reduction, a considerable loss of lean body mass is also observed. How these effects compare to conventional caloric restriction is unclear. The aim of the current study was to compare the effects of semaglutide injections and energy-matched caloric restriction on skeletal muscle mass, function and exerc…
-
585.
Comparative cardiovascular data on glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in atherosclerotic cardiovascular disease (ASCVD) without diabetes are limited. This propensity score-matched retrospective TriNetX study compared adults aged ≥45 years with body mass index ≥27 kg/m After matching, 5665 patients were analyzed per group. No statistically significant differences were observed between semaglutide and tirzepatide i…
-
586.
Lymph node metastasis (LNM) is a major determinant of poor prognosis in oral squamous cell carcinoma (OSCC) and remains difficult to treat due to the immunosuppressive tumor microenvironment and limited response to immune checkpoint blockade. Here, we report a biomimetic nanotherapeutic platform designed to induce triaptosis and enhance antitumor immunity for the treatment of metastatic OSCC. Semaglutide-loaded cerium oxide nanoparticles were engineered and further coated with macrophage membran…
-
587.
GLP-1 and dual GLP-1/GIP receptor agonists have improved obesity treatment, but their high cost requires economic evaluation to guide resource allocation. To assess the short-term cost-effectiveness of subcutaneous tirzepatide, semaglutide, and liraglutide for treating adults with overweight or obesity without diabetes in Iran. A decision-tree model was developed to compare tirzepatide, semaglutide, and liraglutide over 68 weeks in adults aged ≥ 18 years with BMI ≥ 30 kg/m² or ≥ 27 kg/m² with at…
-
588.
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight reduction, yet most clinical trials lack ethnic diversity, limiting the generalizability of these outcomes. This is a retrospective, single-centre study that evaluates 12-month weight loss…
-
589.
tirzepatide is associated with greater glycemic control and weight reduction compared to semaglutide in patients with T2D. Tirzepatide has also been recently shown to be non-inferior to dulaglutide in cardiovascular risk reduction among patients with T2D. Whether tirzepatide is more or less effective than semaglutide for cardioprotection is underexplored. The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and com…
-
590.
Canada approved its first generic version of semaglutide on April 28, 2026, 114 days after market exclusivity on the brand-name product expired and 26 months after the first generic company filed. Neither Health Canada nor the manufacturers appear to have missed a regulatory deadline. The delay arose because Health Canada had never set out how a manufacturer should establish that a fully synthetic semaglutide is the same drug as a semisynthetic reference product, so the agency and the companies…
-
591.
Obesity is a complication of childhood craniopharyngioma that remains difficult to treat. We investigated whether semaglutide was associated with a decrease in BMI among adolescents with craniopharyngioma-related obesity. This multicentre retrospective study included 20 patients < 18 years old with craniopharyngioma and obesity (BMI > 2 WHO Z-score) from 2019 to 2024 (source population: 139 children with craniopharyngioma, including 36 children with obesity). They received off-label semaglutide…
-
592.
Both the GLP-1 receptor agonist semaglutide and the novel dual GIP/GLP-1 receptor agonist tirzepatide have emerged as first-line therapeutic options for metabolic diseases. However, their real-world comparative safety profiles are difficult to interpret due to differential reporting composition in spontaneous reporting databases. This study compared their post-marketing adverse event (AE) reporting patterns and examined how reporter identity influences signal prominence. AE reports (May 2022-Jun…
-
593.
Real-world long-term data on oral semaglutide are limited. We evaluated its 24-month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). This retrospective real-world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic. Changes in HbA1c, body weight, eGFR, urinary albumin-to-creatinine ratio (UACR) and lipid profile were assessed using linear mixed models. The composite endpoint of HbA1c ≤ 7% and ≥ 5% weight loss was assessed over…
-
594.
To develop a next-generation, longer-acting, more-clinical-benefits agonist to achieve sustained efficacy with improved tolerability. CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays. Pharmacokinetics were profiled in SD rats; metabolic efficacy was evaluated in B6/ob and DIO mice (CT130 biweekly vs semaglutide weekly). Receptor trafficking dynamics and cholesterol regulation were dissected mechanistically. Toxicology was assessed in…
-
595.
To characterise postmarketing safety signals and medication-use risks associated with GLP-1 receptor agonists and the GIP/GLP-1 co-agonist tirzepatide in diabetes and obesity care using an integrated pharmacovigilance, utilisation-context, regulatory, and external-consistency framework. FDA Adverse Event Reporting System (FAERS) data from 2021Q1 through 2026Q1 were processed using deleted-case exclusion, latest-case-version retention, and case-product deduplication with analysis at the GLP-1 pri…
-
596.
Glucagon-like peptide-1 receptor (GLP-1R) ligands including semaglutide play an important role in drug discovery. Herein, a short semaglutide-derived GLP-1R-engaging segment was used as the basis for scaffold construction, and conformational restabilisation was introduced through lactam stapling and bulky aromatic non-natural amino acid substitution. A total of 108 stapled peptide candidates were designed by structure-guided modelling and virtual screening. Among them, 35 peptides were synthesis…
-
597.
To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment. In this prospective observational study, 53 patients received sleeve gastrectomy ( At 1 year, all groups lost weight; the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group…
-
598.
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide…
- 599.
-
600.
Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subc…
-
601.
To examine disordered eating attitudes and behaviors in individuals treated with semaglutide 2.4 mg or placebo for 60 weeks. Individuals seeking obesity treatment (n = 120) randomized (3:2) to semaglutide or placebo, both with lifestyle intervention, were assessed at baseline and Weeks 20, 40, and 60. At each assessment, clinicians evaluated binge eating and eating disorder psychopathology (Eating Disorder Examination), and questionnaires measured loss of control (Loss of Control Over Eating Sca…
-
602.
Cagrilintide-semaglutide (CagriSema) 2·4 mg each has shown clinically meaningful bodyweight reductions in global phase 3 studies. Different dosing options might support individual treatment responses and tolerability. We aimed to investigate the efficacy and safety of once per week subcutaneous cagrilintide-semaglutide 1·7 mg each or 1·0 mg each versus placebo in participants with obesity or overweight and at least one obesity-related complication. This multicentre, randomised, double-blind with…
- 603.
-
604.
Incretin mimetics like semaglutide and peptide YY3-36 (PYY3-36) reduce appetite and body weight, however their individual and combined effects on bone in the setting of metabolic disease and associated osteoporosis (MetOP) lack mechanistic insights. Here, female Wistar rats were randomized to: [1] Healthy control, [2] MetOP-Saline, [3] MetOP-Sema, [4] MetOP-PYY, [5] MetOP-Sema+PYY. Animals in group 2-5 received a "Western diet" in combination with nitric oxide synthase inhibitor L-NAME to induce…
-
605.
Weight loss with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is heterogeneous across individuals, yet the genetic causes of this variation are not fully known. We integrated exome sequencing data with electronic health records within the Helix Research Network (n = 351,818). Here, we show that, among 13,725 GLP-1RA-treated adults, carriers of rare damaging GLP1R variants lose less weight with semaglutide than matched non-carriers but achieve a near-normal tirzepatide response. Carriers…
-
606.
Rapid weight loss, as induced by GLP-1 receptor agonists, is accompanied by pronounced muscle loss. GDF8 (myostatin) and activin A (ActA), acting via ActRIIA/B receptors, are negative regulators of muscle mass. The aim of this study was to evaluate the effect of antibodies blocking GDF8 (trevogrumab) and ActA (garetosmab) on semaglutide-induced weight and muscle loss. COURAGE is a two-part, phase 2, double-blind, placebo-controlled, randomised trial. This multicentre (60 sites), US-based trial e…
-
607.
In the Semaglutide Cardiovascular Outcomes Trial (SOUL), oral semaglutide reduced the risk of a first 3-point major adverse cardiovascular event (3-P MACE; including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular [CV] death). Total event analyses, assessing both first and subsequent events, can contribute to a better understanding of the impact of interventions on the total burden of disease; however, the effects of oral semaglutide on subsequent events are unknown. To evalu…
- 608.
-
609.
Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used in females of reproductive age for glycemic control and weight management, with emerging evidence suggesting benefits on fertility and obstetrical outcomes. However, pregnancy safety data remain limited, and current guidance advises discontinuation before conception due to uncertain fetal exposure risk. Since many pregnancies are unplanned, inadvertent exposures are inevitable-further data is needed to inform clinical…
- 610.
-
611.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown. The objective was to compare the effectiveness of semaglutide versus tirzepatide on the risk of major adverse cardiovascular events (MACE) in individuals with overwe…
-
612.
Obesity is a chronic, relapsing metabolic disorder associated with insulin resistance, dyslipidemia, and related complications. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide (SEMA), exhibit robust therapeutic efficacy, their clinical application is limited by low oral bioavailability. Here, we report a dual-transporter-targeted oral nanomicellar platform (SGT-M) designed to overcome these limitations. SEMA was electrostatically complexed with glucosamin…
Preprints (not yet peer-reviewed)
2-
613.
Glucagon-like peptide-1 (GLP-1) receptor agonists — including semaglutide (Ozempic®, Wegovy®) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro®, Zepbound®) — have transformed the management of type 2 diabetes, obesity, and cardiovascular disease. Yet a clinically significant and underappreciated challenge persists: profound inter-individual variability in both efficacy and tolerability. Some patients lose more than 20% of body weight; others less than 5%. Some experience debilitating nausea;…
-
614.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform integrating 23 million de-identified U.S. patient records, we analyzed 135,349 individuals treated with GLP-1RAs and stratified them as “super responders” (>15% weight loss), “moderate responders” (5–15% weight loss), “minimal weight-loss group” (<5% weight loss), and “weight regainers”. super responders reve…
Case Reports
10-
615.
With the increase in use of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) in the population, nuclear medicine physicians should be aware of the possibility of nondiagnostic FDG PET scans due to these medications, which work partly by increasing insulin secretion. We demonstrate a case where a patient's use of such a medication presumptively led to muscular and myocardial uptake, complicating scan interpretation considerably. Clinicians should be aware of the presence of…
-
616.
Semaglutide, a glucagon-like peptide-1 receptor agonist widely used for managing type 2 diabetes mellitus and obesity. Reports of semaglutide-associated hepatotoxicity are exceedingly rare. We detail a case of a 44-year-old woman who developed liver injury with elevated liver enzymes after semaglutide initiation for weight management. Liver enzyme levels normalized after discontinuing the drug and worsened upon rechallenge, confirming semaglutide's potential to cause liver injury. In addition, o…
-
617.
Glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide (Mounjaro), are widely used to manage type 2 diabetes mellitus (T2DM) and obesity. While gastrointestinal side effects are common, acute pancreatitis remains a rare but significant complication. Limited evidence exists on the risks associated with switching between GLP-1 agonists, emphasizing the need for clinical awareness. We present a 59-year-old male with T2DM, hyperlipidemia, and hypertension, who was recently transiti…
-
618.
Lithium is a mainstay treatment for bipolar disorder, but its narrow therapeutic index and susceptibility to pharmacokinetic interactions make appropriate monitoring crucial. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are increasingly prescribed for type 2 diabetes and weight management. Scarce evidence exists on the potential interaction between semaglutide and lithium. We present 3 cases involving patients on stable lithium regimens who were initiated on semagl…
-
619.
Long-acting glucagon-like peptide-1 receptor agonists have traditionally been used for glycemic control in type 2 diabetes mellitus. More recently, the medical community in the United States has used its most common side effect, weight loss, as an adjunct therapy for weight management in certain populations. Little is known about the effects of semaglutide in pregnancy. But in nonpregnant people, nausea, vomiting, decreased appetite, and abdominal cramping are common side effects. Here we presen…
-
620.
Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant ga…
-
621.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) facilitate weight loss. Weight regain off therapy is concerning. We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with…
-
622.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, are increasingly used for the treatment of type 2 diabetes mellitus and for weight management. Although generally effective, specific end-organ effects, including delayed gastric emptying, may impact the perioperative care of patients receiving these agents. Given these concerns, guidelines have been suggested for the perioperative care of patients receiving GLP-1 RAs. However, these recommendations do not specifically…
-
623.
Vasovagal syncope (VVS) is the most common form of cardiovascular dysautonomia that has multiple etiologies. Post-vaccination dysautonomia, in the form of VVS and postural orthostatic tachycardia syndrome, has been reported in the literature after various vaccines, including COVID-19 mRNA vaccination. Treatment of post-vaccination syndromes has not been explored leaving patients with post-vaccination dysautonomia with limited therapeutic options. We report a 42-year-old woman who developed post-…
-
624.
Latent Autoimmune Diabetes in Adults (LADA) is a complex form of autoimmune diabetes characterised by the presence of pancreatic autoantibodies and a progressive β-cell decline, often leading to eventual insulin dependence. Evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RAs)-notably semaglutide-in LADA remains limited. Here, we present the case of a 55-year-old woman, initially diagnosed with type 2 diabetes mellitus, who exhibited class II obesity and multiple autoimmune di…
Curated sources on file
101- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43.
- 44.
- 45.
- 46.
- 47.
- 48.
- 49.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.
- 61.
- 62.
- 63.
- 64.
- 65.
- 66.
- 67.
- 68.
- 69.
- 70.
- 71.
- 72.
- 73.
- 74.
- 75.
- 76.
- 77.
- 78.
- 79.
- 80.
- 81.
- 82.
- 83.
- 84.
- 85.
- 86.
- 87.
- 88.
- 89.
- 90.
- 91.
- 92.
- 93.
- 94.
- 95.
- 96.
- 97.
- 98.
- 99.
- 100.
- 101.